

(51) International Patent Classification:
C12Q 1/68 (2006.01)(21) International Application Number:
PCT/US2015/029986(22) International Filing Date:
8 May 2015 (08.05.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/990,598 8 May 2014 (08.05.2014) US
62/079,495 13 November 2014 (13.11.2014) US(71) Applicant: FLUIDIGM CORPORATION [US/US];
7000 Shoreline Court, Suite 100, South San Francisco,
California 94080 (US).(72) Inventors: WEST, Jason A. A.; 7000 Shoreline Court,
Suite 100, South San Francisco, California 94080 (US).
FOWLER, Brian; 7000 Shoreline Court, Suite 100, South
San Francisco, California 94080 (US). CHARN, Tze-
Howe; 7000 Shoreline Court, Suite 100, South San Fran-
cisco, California 94080 (US). JOHNSON, Christian F.;7000 Shoreline Court, Suite 100, South San Francisco,
California 94080 (US). UNGER, Marc A.; 7000 Shoreline
Court, Suite 100, South San Francisco, California 94080
(US).(74) Agents: APPLE, Randolph T. et al.; Kilpatrick Townsend
& Stockton LLP, Two Embarcadero Center, Eighth Floor,
San Francisco, California 94111 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,

[Continued on next page]

(54) Title: INTEGRATED SINGLE CELL SEQUENCING




FIG. 1

(57) Abstract: This disclosure provides a method of forming tagged nucleic acid sequences. A target polynucleotide is immobilized on a solid support; a recognition-oligonucleotide is hybridized thereto; the recognition-oligonucleotide-target polynucleotide hybrid is cleaved; and an adapter nucleic acid is ligated to the cleaved target polynucleotide, thereby forming a tagged nucleic acid sequence. Also provided is a method of forming a tagged single stranded cDNA; a method of forming a plurality of tagged heterogeneous nucleic acid sequences; a library of recognition-oligonucleotides; and methods for amplifying a cDNA sequence immobilized on a solid support. These methods and products can be used alone or in combination for integrated single cell sequencing, and can be adapted for use in a microfluidic apparatus or device.



TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

INTEGRATED SINGLE CELL SEQUENCING

RELATED APPLICATIONS

[0001] This application claims the priority benefit of U.S. provisional patent application 61/990,598, filed May 8, 2014; and U.S. provisional patent application 62/079,495, filed November 13, 2014. The two aforesaid priority applications are hereby incorporated herein by reference in their entirety for all purposes.

FIELD OF THE INVENTION

[0002] The invention relates to nucleic acid assays and finds application in the fields of genetics, medicine and agriculture. The methods and compositions provided herein are useful for nucleic acid sequencing and gene expression analysis in heterogeneous cell populations.

BACKGROUND

[0003] Nucleic acid sequencing is the process of determining the nucleotide order of a given nucleic acid fragment. The original chain termination method of sequencing uses sequence-specific termination of a DNA synthesis reaction using modified nucleotide substrates. New sequencing technologies are being developed to increase the speed and reduce the cost of determining the sequence of nucleic acid in a biological sample, such as a genome or an expression library. Such methods can be applied commercially, for example, to identify, diagnose, and potentially develop treatments for genetic or contagious diseases.

SUMMARY OF THE INVENTION

[0004] This disclosure provides a method of forming tagged nucleic acid sequences. A target polynucleotide is immobilized on a solid support; a recognition-oligonucleotide is hybridized thereto; the recognition-oligonucleotide-target polynucleotide hybrid is cleaved; and an adapter nucleic acid is ligated to the cleaved target polynucleotide, thereby forming a tagged nucleic acid sequence. Also provided is a method of forming a tagged single stranded cDNA; a method of forming a plurality of tagged heterogeneous nucleic acid sequences; a library of recognition-oligonucleotides; and methods for amplifying a cDNA sequence immobilized on a solid support. These methods and products can be used alone or in combination for integrated single cell sequencing, and can be adapted for use in a microfluidic apparatus or device.

[0005] A method of forming a tagged nucleic acid sequence according to this invention can include the steps of: (i) immobilizing a target polynucleotide on a solid support, thereby forming an immobilized target polynucleotide; (ii) hybridizing a recognition-oligonucleotide to said immobilized target polynucleotide, thereby forming a recognition-oligonucleotide-target polynucleotide hybrid; (iii) cleaving said recognition-oligonucleotide-target polynucleotide hybrid with a cleaving agent, thereby

forming a cleaved recognition-oligonucleotide-cleaved target polynucleotide hybrid comprising a cleaved target polynucleotide; and (iv) ligating an adapter nucleic acid sequence to said cleaved [0006]

Also provided is a method of forming a plurality of tagged heterogeneous polynucleotides. This can include the steps of: (i) immobilizing a plurality of heterogeneous target polynucleotides on a solid support, thereby forming a plurality of immobilized heterogeneous target polynucleotides; (ii) hybridizing a plurality of heterogeneous recognition-oligonucleotides to said immobilized heterogeneous target polynucleotides, thereby forming a plurality of recognition-oligonucleotide-target polynucleotide hybrids; (iii) cleaving said recognition-oligonucleotide-target polynucleotide hybrids with a cleaving agent, thereby forming a plurality of cleaved recognition-oligonucleotide-cleaved target polynucleotide hybrids; and (iv) ligating an adapter nucleic acid sequence to said plurality of cleaved target polynucleotides, thereby forming a plurality of tagged heterogeneous polynucleotides.

[0007] Also provided is a method of forming a tagged single stranded cDNA. This can include the steps of: (i) immobilizing a target cDNA on a solid support, thereby forming an immobilized target cDNA; (ii) hybridizing a recognition-oligonucleotide to said immobilized target cDNA, thereby forming a recognition-oligonucleotide-cDNA hybrid; (iii) cleaving said recognition-oligonucleotide-cDNA hybrid with a cleaving agent, thereby forming a cleaved recognition-oligonucleotide-cleaved cDNA hybrid; and (iv) ligating an adapter nucleic acid to said cleaved cDNA, thereby forming a tagged single stranded cDNA.

[0008] This invention further provides a method of forming a tagged nucleic acid sequence. This can include: (i) immobilizing a target ribonucleic acid on a solid support, thereby forming an immobilized target ribonucleic acid (RNA); (ii) synthesizing a complementary DNA (cDNA) strand, thereby forming an RNA:cDNA hybrid; (iii) cleaving the RNA:cDNA hybrid with an RNA:cDNA cleaving agent, to generate a cleaved RNA:cDNA hybrid, wherein the cDNA comprises a ligatable end; (iv) ligating an adapter oligonucleotide to the ligatable end; and (v) removing the ribonucleic acid sequence from said RNA:cDNA hybrid, thereby forming a tagged nucleic acid sequence.

[0009] Also provided is a method of forming a plurality of tagged heterogeneous nucleic acid sequences. This can include: (i) immobilizing a plurality of heterogeneous target ribonucleic acid sequences on a solid support, thereby forming a plurality of immobilized heterogeneous target ribonucleic acid sequences; (ii) reverse transcribing said immobilized heterogeneous target ribonucleic acid sequences, thereby forming a plurality of heterogeneous RNA:DNA hybrids; (iii) cleaving said plurality of heterogeneous RNA:DNA hybrids with an RNA:DNA cleaving agent, thereby forming a plurality of cleaved RNA:DNA hybrids; (iv) ligating an adapter nucleic acid sequence to said plurality of cleaved RNA:DNA hybrids; and (v) removing said ribonucleic acid sequences from said cleaved RNA:DNA hybrids, thereby forming a plurality of tagged heterogeneous nucleic acid sequences.

[0010] Such methods can be used to prepare a library of recognition-oligonucleotides that comprise a plurality of heterogeneous recognition-oligonucleotides each comprising a restriction enzyme recognition sequence flanked by degenerate nucleic acid sequences. The cleaving agent may be a restriction enzyme, and the library may be included as part of a microfluidic device.

[0011] This invention further provides a method of amplifying a cDNA sequence. This can include: (i) immobilizing an RNA molecule extracted from an isolated cell on a solid support, thereby forming an immobilized ribonucleic acid sequence; (ii) reverse transcribing said immobilized ribonucleic acid sequence, thereby forming an immobilized RNA:DNA hybrid; (iii) removing said ribonucleic acid sequence from said RNA:DNA hybrid, thereby forming an immobilized cDNA sequence; (iv) hybridizing a recognition oligonucleotide to said immobilized cDNA sequence, thereby forming a recognition- oligonucleotide:DNA hybrid; (v) cleaving said recognition oligonucleotide:cDNA hybrid with a cleaving agent, thereby forming a cleaved recognition oligonucleotide:cleaved cDNA hybrid; (vi) ligating an adapter nucleic acid sequence to said cleaved cDNA, thereby forming a tagged cDNA sequence; (vii) hybridizing said tagged cDNA sequence to an amplification nucleic acid sequence under conditions allowing for PCR amplification, thereby amplifying a cDNA sequence.

[0012] Another method provided in this disclosure is a method of amplifying a cDNA sequence. This can include (i) immobilizing an RNA molecule extracted from an isolated cell on a solid support, thereby forming an immobilized ribonucleic acid sequence; (ii) reverse transcribing said immobilized ribonucleic acid sequence, thereby forming an immobilized RNA:DNA hybrid; (iii) cleaving said RNA:DNA hybrid with an RNA:DNA cleaving agent, thereby forming a cleaved RNA:DNA hybrid; (iv) ligating an adapter nucleic acid sequence to said cleaved RNA:DNA hybrid; (v) removing said ribonucleic acid from said cleaved RNA:DNA hybrid, thereby forming a tagged cDNA sequence; and (vi) contacting said tagged cDNA sequence with an amplification nucleic acid sequence under conditions allowing for PCR amplification, thereby amplifying said cDNA sequence.

[0013] In one aspect, a method of forming a tagged nucleic acid sequence is provided. The method involves (i) immobilizing a target ribonucleic acid on a solid support, thereby forming an immobilized target ribonucleic acid (RNA); (ii) synthesizing a complementary DNA (cDNA) strand, thereby forming an RNA:cDNA hybrid; (iii) cleaving the RNA:cDNA hybrid with an RNA:cDNA cleaving agent, to generate a cleaved RNA:cDNA hybrid, wherein the cDNA comprises a ligatable end; (iv) ligating an adapter oligonucleotide to the ligatable end ; and (v) removing the ribonucleic acid sequence from said RNA:cDNA hybrid, thereby forming a tagged nucleic acid sequence. An embodiment of this approach is illustrated in **Figs. 1-7**.

[0014] In a further aspect, a method of forming a tagged nucleic acid sequence is provided. The method involves (i) immobilizing a target ribonucleic acid on a solid support, thereby forming an immobilized target ribonucleic acid (RNA); (ii) synthesizing a complementary DNA (cDNA) strand and removing the target RNA; (iii) hybridizing a recognition-oligonucleotide to the immobilized target cDNA, thereby forming a recognition-oligonucleotide:cDNA hybrid; (iii) cleaving the recognition-oligonucleotide:cDNA hybrid with a cleaving agent, thereby forming a cleaved recognition-oligonucleotide:cleaved cDNA hybrid, wherein the cDNA comprises a ligatable end; and (iv) ligating an adapter oligonucleotide to the ligatable end, thereby forming a tagged nucleic acid sequence. An embodiment of this approach is illustrated in **Figs. 8-9**.

[0015] Other inventive products, methods, and features that can be used alone or in combination with the aforesaid products and methods are evidenced by the description and examples that follow.

BRIEF DESCRIPTION OF THE DRAWINGS

[0016] **Fig. 1** is a stepwise depiction of a method for tagging immobilized nucleic acid sequences.

[0017] **Fig. 2** illustrates an RNA annealed to an anchor polynucleotide. **Fig. 3** illustrates a first strand cDNA and RNA:cDNA hybrid. **Fig. 4** illustrates the result of cleaving an RNA:cDNA hybrid using a restriction endonuclease. **Fig. 5** illustrates an adaptor oligonucleotide ligated to the free 3' end of the cleaved cDNA molecule.

[0018] **Fig. 6A** illustrates a related approach in which the single-stranded overhang of RNA:cDNA hybrid is contributed by the cDNA molecule. **Fig. 6B** illustrates another approach in which the single-stranded overhang of RNA:cDNA hybrid is contributed by the RNA molecule. **Fig. 7** illustrates the result of removing the RNA from the RNA:cDNA hybrid.

[0019] **Fig. 8** is a stepwise depiction of another method for tagging immobilized nucleic acid sequences in which a cDNA:Oligonucleotide hybrid is cleaved. **Fig. 9** is a stepwise depiction of another method for tagging immobilized nucleic acid sequences in which a cDNA is amplified on a surface.

[0020] **Figs. 10, 11, 12, and 13** illustrate different steps in the synthesis of the cDNA second strand by bridge amplification. **Fig. 14** shows how one of the strands may be removed before sequencing, which results in a lawn of single strands to be sequenced. **Figs. 15 and 16** illustrate so-called wildfire amplification in which polyadenylated mRNA is prepared by hybridizing to an immobilized poly(T) sequence. **Fig. 17** illustrates on-chip sequencing using a bead-based sequencing reaction.

[0021] **Fig. 18** is a fluorescence image showing that signals from individual beads can be distinguished when sequencing beads (or a surrogate) are separated by filler beads. **Fig. 19** is another fluorescence image showing how to distinguish individual sequencing beads in the absence of filler beads.

[0022] **Fig. 20** is a depiction in which mRNA and beads are combined before entry into the first chamber, following which amplification and sequence imaging are carried out in a second chamber.

[0023] **Fig. 21** is a chart showing possible chemistry for attachment of nucleic acids to a surface. **Fig. 22** is a stepwise depiction of the conjugation of an oligonucleotide onto a glass surface.

[0024] **Fig. 23** is an example of an apparatus in which signal from the second chamber is collected using a camera.

DETAILED DESCRIPTION OF THE INVENTION

[0025] Provided herein are methods and compositions for tagging and amplifying nucleic acid sequences. The methods and compositions provided are useful for, *inter alia*, single cell sequencing procedures and may be used to determine RNA expression profiles of individual cells of a heterogeneous cell population.

[0026] **Part 1** describes methods for tagging immobilized nucleic acid sequences.

[0027] **Part 2** describes amplification and sequencing tagged nucleic acid sequences.

[0028] **Part 3** methods for sequencing and data collection.

[0029] **Part 4** describes integrated microfluidic devices.

[0030] **Part 5** describes additional description about certain elements described in Parts 1-4.

PART 1: Methods for Tagging Immobilized Nucleic Acid Sequences

[0031] In one aspect the invention relates to immobilizing a target RNA, producing a cDNA sequence complementary to at least a portion of the target RNA, cleaving the cDNA sequence to produce a new free terminus, and tagging the cDNA by ligating an adaptor sequence to the new free terminus.

1. First Approach – In which a cDNA:RNA hybrid is cleaved

1.1. Produce cDNA

[0032] A first approach is summarized in FIG. 1 and illustrated in FIGS. 2 to 6B. It will be appreciated that FIGS. 1-6 show an exemplary embodiment, to which the invention is not limited, and that a variety of variations are discussed herein below or will be apparent to the reader. In the illustrated embodiment, an RNA 200, typically a mRNA, is immobilized (or “captured”) on a surface 100. See FIG. 2. In some embodiments surface 100 is a bead. In other embodiments the surface may be substantially planar. As illustrated, the RNA may be captured by annealing to anchor polynucleotide 50 which is immobilized on the surface. In one approach a polyA tail 55 of the mRNA anneals to an oligo d(T) portion 51 of the anchor polynucleotide. Oligo d(T) portion 51 is suitable for priming a polymerase (e.g., reverse transcriptase) reaction, e.g., and comprises a free 5' end (FIG. 2). In some embodiments the RNA is annealed to a sequence of the anchor polynucleotide other than oligo d(T), such as a transcript specific sequence. In some embodiments the RNA does not comprise a poly(A) tail. For simplicity, the RNA will be referred to as mRNA and the capture sequence to which the RNA anneals will be referred to as an oligo d(T) capture sequence.

[0033] As discussed in greater detail below, in some embodiments the anchor polynucleotide comprises, in addition to oligo d(T) capture sequence, an amplification primer sequence (AP1') 53. The anchor polynucleotide may also comprise a cut site sequence (CS2) 52. The cut site sequence may be a restriction endonuclease recognition sequence

[0034] The immobilized mRNA is reverse transcribed from the oligo d(T) primer, producing 1st strand cDNA 301 and RNA:cDNA hybrid 300 (FIG. 3) immobilized on the surface. Following the polymerization reaction, optionally the reverse transcriptase may be inactivated, e.g., by heating.

1.2. Cleave RNA:cDNA hybrid

[0035] The RNA:cDNA hybrid is cleaved using a restriction endonuclease (RE) to produce a free RNA 5' terminus and a free DNA 3' terminus (FIG. 4). The RE cleaves at a restriction site (RST1:RST1') in the cDNA:RNA hybrid. In one embodiment the termini resulting from the cleavage are staggered creating a sticky end (FIG. 4). In one embodiment the RE creates a blunt end. Features of the RE are discussed below. After the cleavage step the RE may be inactivated (e.g., heat inactivated).

1.3. Ligate Adaptor Oligonucleotide

[0036] An adaptor oligonucleotide 310 is ligated to the free 3' end of the cleaved cDNA molecule, e.g., using a DNA ligase. Any suitable method of ligation may be used. As illustrated in FIG. 5, the adaptor oligonucleotide comprises a second copy of amplification primer sequence (AP1') 53.

[0037] In one approach, ligation of the adaptor oligonucleotide comprises annealing a partially double stranded polynucleotide 320 (one strand of which is the adaptor oligonucleotide) to a sticky end created by the RE cleavage. The nature of the sticky end will depend, typically, on the choice of RE. In one approach, a single-stranded overhang of cleaved RNA:cDNA hybrid is contributed by the template mRNA molecule, as illustrated in FIG. 4. In this approach, a partially double-stranded adaptor construct, in which a protruding strand is complementary to the single-stranded overhang of the RNA molecule, is annealed to the RNA. The 5' end of the protruding strand of the adaptor is ligated to the 3' end of the cleaved cDNA, thereby producing a tagged nucleic acid molecule.

[0038] In a related approach, the single-stranded overhang of RNA:cDNA hybrid is contributed by the cDNA molecule, as illustrated in FIG. 6A. In this approach, a partially double-stranded adaptor construct, in which a protruding strand has is complementary to the single-stranded overhang of the cDNA molecule, is annealed to the cDNA. The 5' end of the non-protruding strand of the adaptor is ligated to the 3' end of the cleaved cDNA, thereby producing a tagged nucleic acid molecule.

[0039] In another approach in which the single-stranded overhang of RNA:cDNA hybrid is contributed by the RNA molecule, a single-stranded adaptor oligonucleotide a 5' region complementary to the single-stranded overhang of the RNA molecule (rather than a partially double-stranded molecule) is annealed RNA, with, as illustrated in Fig. 6B. The 5' end of the single-stranded adaptor oligonucleotide is ligated to the 3' end of the cleaved cDNA, thereby producing a tagged nucleic acid molecule.

[0040] In another embodiment, the adaptor does not anneals directly adjacent to the cDNA, and a polymerase is used for gap filling prior to ligation.

[0041] In another approach, cleavage of the cDNA:RNA hybrid creates a blunt end. Ligation of the adaptor oligonucleotide can be accomplished by ligating a double stranded polynucleotide comprising adaptor oligonucleotide 310 to the blunt end. This results in a heterogeneous mixture of identically tagged cDNA molecules.

[0042] An exemplary ligase for ligation of an oligonucleotide to a single stranded cDNA is T4 RNA ligase 1 (Troutt et al., 1992, *Proc. Natl. Acad. Sci. USA.* 89:9823-25), optionally in the presence of hexamine cobalt chloride.

[0043] After the ligation step the ligase may be inactivated (e.g., heat inactivated).

1.4. Remove RNA

[0044] The RNA is removed from the RNA:cDNA hybrid. The RNA may be removed enzymatically, chemically, or thermally. In some embodiments the RNA is degraded. The result is an immobilized bound single-stranded cDNA tagged with an adaptor (**FIG. 7**), *i.e.*, a tagged nucleic acid molecule. In one embodiment RNA is removed from the hybrid using a ribonuclease, such as RNase H.

1.5. Multiple Adaptor Oligonucleotides

[0045] Often, as illustrated in the drawings, a single adaptor oligonucleotide **310** is used. However, in some embodiments, two or more different adaptor oligonucleotides are used. In one approach, the different adaptor oligonucleotides are compatible with different RE sites, allowing RNAs with different RE sites to be processed in the same reaction.

[0046] In a different example, different adaptor oligonucleotides are distinguished by having different AP1' sequences. For example, a first cDNA anchor oligonucleotide **50** comprising a first AP1' sequence **53**, a first sequence-specific capture sequence, a first restriction site, and an adaptor oligonucleotide comprising the first AP1' sequence may be used in combination with a second anchor oligonucleotide **50** comprising a second AP1' sequence **53**, a second-sequence specific capture sequence different from the first, a second restriction site, and an adaptor oligonucleotide comprising the second AP1' sequence. In this fashion it is possible using multiple sequence specific capture sequences, to produce a heterogeneous mixture in which some nucleic acid species (e.g., cDNA) are tagged with one tag and some nucleic acid species (e.g., cDNA) are tagged with a different tag.

1.6. Additional Processing Steps

[0047] Typically, the immobilized tagged nucleic acid molecule is subjected to additional processing steps, such as clonal amplification on the surface, and sequencing, as discussed below.

2. Second Approach – In which a cDNA:Oligonucleotide hybrid is cleaved

[0048] A second tagging approach is illustrated in **FIGS. 8-9**. It will be appreciated that **FIGS. 8-9** show a certain embodiment, to which the invention is not limited, and that a variety of variations are discussed herein below or will be apparent to the reader.

2.1. Produce cDNA

[0049] In this embodiment, an mRNA **60** is immobilized on a surface (e.g., bead) **61** as described in §1.1, above, e.g., via annealing of a polyA tail to an immobilized oligo d(T)-containing anchor polynucleotide. The immobilized mRNA is reverse transcribed, as also described in §1.1, above, to produce an RNA:cDNA hybrid **62** in which the first strand cDNA **63** is immobilized on the surface.

2.2. Remove RNA

[0050] The RNA is removed from the hybrid, e.g., using chemical, thermal or enzymatic methods, such as treatment with a ribonuclease such as RNase H, leaving the single-stranded immobilized cDNA.

2.3. Produce cDNA: Recognition Oligonucleotide Hybrid

[0051] The immobilized cDNA is subsequently hybridized to a recognition oligonucleotide **64**, which is at least partially complementary to a portion of the cDNA, rendering a portion of the cDNA

double-stranded and susceptible to digestion with a restriction endonuclease. The degree of complementarity between the cDNA and the recognition oligonucleotide is a degree sufficient to result in a double-stranded region (e.g., the cDNA:oligo hybrid) that can be recognized by a specified restriction endonuclease, which recognizes the oligonucleotide:cDNA hybrid and cleaves the cDNA. Typically the recognition oligonucleotide will be at least 12, usually at least 15 and sometimes at least 25 bases in length.

[0052] In some embodiments, an assay is carried out using a single recognition oligonucleotide. In some embodiments multiple different recognition oligonucleotides are used. When different recognition oligonucleotides are used, they may anneal to different cDNA sequences to create double-stranded regions recognized by different restriction endonucleases. Alternatively, they may anneal to different cDNA sequences to create double-stranded regions recognized by the same restriction endonuclease, but having flanking sequences (for example) that increase the stability of the oligo:cDNA hybrid. This provides increased flexibility when working with a populations of highly heterogeneous sequences, because a combination of different restriction endonucleases to generate a ligatable end, or a single restriction endonuclease may be used to generate ligatable ends from substrates with diverse restriction site or flanking sequences.

[0053] In some cases a degenerate population of recognition oligonucleotides, as described in **Section 4.2**, is used to generate ligatable ends of a heterogeneous population.

2.4. Cleave cDNA:Oligonucleotide hybrid

[0054] The oligonucleotide:cDNA hybrid comprising a restriction endonuclease recognition site is recognized by a specified restriction endonuclease (or endonucleases) cleaves the immobilized cDNA. The action of the RE produces a free 3' cDNA terminus. Depending on the choice of recognition oligonucleotide(s) and restriction endonuclease(s), the immobilized cleavage product can have a blunt end or sticky end. The sticky end can comprise a single-stranded overhang contributed by the cDNA or by the recognition oligonucleotide, analogous to the cDNA:RNA cleavage products discussed above in §1.3, above, for RNA:cDNA hybrids.

2.5. Ligate Adaptor Oligonucleotide

[0055] An adaptor oligonucleotide may be ligated to the free 3' end of the cleaved cDNA molecule, analogous to the description in §1.3 above for RNA:cDNA hybrids, resulting in a tagged cDNA or, more generally, a surface or plurality of surfaces comprising a heterogeneous population of tagged immobilized cDNAs.

2.6. Additional Processing Steps

[0056] Typically, the immobilized tagged nucleic acid molecule is subjected to additional processing steps, such as clonal amplification on the surface, and sequencing, as discussed below.

3. Selection Of A Restriction Endonuclease(s)/Restriction Endonuclease Recognition Site(s)

3.1. General Properties


[0057] As discussed above, prior to addition of the Adaptor Oligonucleotide, the cDNA:RNA hybrid or the cDNA:Recognition Oligonucleotide hybrid is cleaved with a restriction endonuclease. As used herein, restriction endonucleases are enzymes that cleave DNA at or near specific recognition

nucleotide sequences (restriction sites). See, e.g., Roberts et al., 2007 "REBASE—enzymes and genes for DNA restriction and modification," *Nucleic Acids Res* 35 (Database issue): D269–70; see <http://rebase.neb.com>). For illustration and not limitation, restriction enzymes for use in the present invention include Type I enzymes (EC 3.1.21.3), Type II enzymes (EC 3.1.21.4), e.g., Type IIs and Type IIP, and Type III enzymes (EC 3.1.21.5). Restriction enzymes occur in nature, may be recombinantly produced, and may be artificial (e.g., comprising sequences from multiple different proteins).

[0058] In some embodiments, the RE produces a 3' protruding sticky end. In some embodiments, the RE produces a 5' protruding sticky end. In some embodiments, the RE produces a blunt end.

[0059] In some embodiments the RE cleaves DNA and RNA strands of a RNA:DNA hybrid.

[0060] In some embodiments, the RE is BaeG1, which recognizes the following restriction site:



[0061] In some embodiments, the RE is a Type-IIs restriction endonuclease that cleaves 2 to 30 nucleotides away from the recognition site. Some Type-IIs endonucleases are "exact cutters" that cut a known number of bases away from their recognition sites. In some embodiments, the overhang of the sticky end is at least 2 bases in length, at least 2 bases in length, at least 3 bases in length, at least 4 bases in length, at least 5 bases in length, at least 6 bases in length, or at least more than 6 bases in length.

[0062] The selection of the restriction endonuclease or restriction endonucleases, and, in the case of the cDNA:Recognition Oligonucleotide hybrid, the design of the Recognition Oligonucleotide sequence takes into account several desired goals.

i) For the *First Approach* -- In which a cDNA:RNA hybrid is cleaved, the enzyme should be capable of cleaving such a hybrid.

ii) The site(s) should be present in a large number of different RNA species, so that a sufficient number of cDNAs is tagged. A "sufficient number" may be most, almost all, a majority, or a subset less than a majority.

iii) The length of the immobilized cleaved cDNA should be sufficient for the sequencing goal (usually at least 15-20 bases) and sufficiently far away from the substrate on which it is immobilized for sequencing reactions to occur. As discussed below, only a portion of the cDNA or genomic sequence is needed to identify many RNA or genomic DNA sequences (e.g., partial sequence is sufficient to identify a specific RNA by reference to a database of known sequences).

iv) The length of the immobilized cleaved cDNAs should be compatible with the amplification method used.

3.2. Cleavage of DNA:RNA hybrids

[0063] For method in which a cDNA:RNA hybrid is cleaved, suitable enzymes will recognize such hybrids. For example and without limitation, suitable enzymes include *Avall*, *AvrII*, *BanI*, *HaeIII*, *HinfI* and *TaqI* (see Murray et al., 2010, Sequence-specific cleavage of RNA by Type II restriction enzymes" *Nucleic Acids Res.* 38:8257–68).

3.3. Cleavage Frequency

[0064] In one approach the restriction enzyme site(s) occurs in the RNA (cDNA) of the source organism at a frequency that allows for the formation of target polynucleotides with an average length of about 250 base pairs, e.g., 50-500 basepairs, or 150-350 basepairs. Preferably, most (e.g., more than 50%, more than 75%, more than 80%, more than 90%, or more than 95%) of the immobilized cDNAs are cleaved and tagged, and of the immobilized tagged cDNAs most (e.g., more than 50%, more than 75%, more than 80%, more than 90%, or more than 95%) have a length of at least 25 bases, or at least 40 bases, or at least 50 bases, or at least 75 bases, or at least 100 bases, or at least 150 bases.

[0065] **Table 1**, below, provides the specificities for a selection of REs and provides the calculated average fragment length based on human genomic DNA (adapted from of New England BioLabs; www.neb.com/tools-and-resources/selection-charts/frequencies-of-restriction-sites). Most RNA samples can be expected to deviate from the frequency and lengths calculated for genomic sequences, but Table 1 illustrates that enzymes (individually or in combination) can be selected to achieve goals (i)-(iii) above. It should be clearly understood that not all of the enzymes in **Table 1** will be useful (e.g., the *BstEII* recognition site may be too infrequent for most samples) and not all of the useful enzymes are included in Table 1 (e.g., *BaeGI* is not in Table 1).

[0066] Alternatively, enzyme(s) can be selected based on empirical analysis of the lengths of cDNAs produced by digestion with the enzyme.

TABLE 1
Cleaving Agents And Frequencies Of Restriction sites In The Human Genome

Enzyme	Specificity	Site Counts	Sites Per Megabase	Average Fragment Length (bp)
<i>BstEII</i>	GGTNACC	335865	114	8746
<i>BamHI</i>	GGATCC	365999	124	8026
<i>SmaI</i>	CCCGGG	376939	128	7793
<i>XmaI</i>	CCCGGG	376939	128	7793
<i>SapI</i>	GCTCTTC	377161	128	7789
<i>SpeI</i>	ACTAGT	400286	136	7339
<i>EcoRV</i>	GATATC	446473	151	6580
<i>Apal</i>	GGGCCC	460339	156	6381
<i>ApaLI</i>	GTGCAC	496255	168	5920
<i>Scal</i>	AGTACT	543793	185	5402
<i>SphI</i>	GCATGC	550951	187	5332
<i>MfeI</i>	CAATTG	564303	192	5206
<i>EciI</i>	GGCGGA	571273	194	5142
<i>HgaI</i>	GACGC	571889	194	5137
<i>AvrII</i>	CCTAGG	594956	202	4938
<i>BciVI</i>	GTATCC	696093	236	4220
<i>BceAI</i>	ACGGC	705176	240	4166
<i>BsaAI</i>	YACGTR	713800	242	4115
<i>FnuDII</i>	CGCG	733938	249	4003

Enzyme	Specificity	Site Counts	Sites Per Megabase	Average Fragment Length (bp)
BclI	TGATCA	738785	251	3976
NcoI	CCATGG	759594	258	3867
BglII	AGATCT	774732	263	3792
EcoRI	GAATTC	847341	288	3467
XbaI	TCTAGA	850998	289	3452
HindIII	AAGCTT	860361	292	3414
NdeI	CATATG	903360	307	3252
StuI	AGGCCT	925728	315	3173
AvallI	ATGCAT	933357	317	3147
BspHI	TCATGA	978289	333	3003
PvuII	CAGCTG	1084260	369	2709
PpuMI	RGGWCCY	1085138	369	2707
AccI	GTMKAC	1101063	374	2668
BscGI	CCCGT	1231061	419	2386
PstI	CTGCAG	1321469	449	2223
BspMI	ACCTGC	1438128	489	2043
FauI	CCCGC	1439772	490	2040
AflIII	ACRYGT	1485394	505	1978
BsmI	GAATGC	1549349	527	1896
HgiCI	GGYRCC	1550876	527	1894
EsaBC3I	TCGA	1603339	545	1832
TaqI	TCGA	1603339	545	1832
PsiI	TTATAA	1647911	560	1783
BfiI	ACTGGG	1706593	580	1721
HhaI	GCGC	1756498	597	1672
HinP1I	GCGC	1756498	597	1672
HpaII	CCGG	2317719	788	1267
SspI	AATATT	2377267	809	1236
SmiI	CTYRAG	2727866	928	1077
NspI	RCATGY	3104357	1056	946
StyI	CCWWGG	3114107	1060	943
SfeI	CTRYAG	3531009	1201	832
BscAI	GCATC	3652924	1243	804
SfaNI	GCATC	3652924	1243	804
MlyI	GAGTC	3931690	1338	747
PleI	GAGTC	3931690	1338	747
Tsp45I	GTSAC	4021757	1369	730
AccI	CCGC	4206123	1431	698
TfiI	GAWTC	4984358	1696	589
CviQI	GTAC	5115077	1741	574
PabI	GTAC	5115077	1741	574
RsaI	GTAC	5115077	1741	574
FokI	GGATG	5201113	1770	565
BbvI	GCAGC	5290042	1800	555

Enzyme	Specificity	Site Counts	Sites Per Megabase	Average Fragment Length (bp)
R1.BceSIV	GCAGC	5290042	1800	555
TseI	GCWGC	5290042	1800	555
Cac8I	GCNNGC	5461330	1859	538
BsrI	ACTGG	5741305	1954	512
HphI	GGTGA	6007328	2044	489
BcoI	CCATC	6170919	2100	476
BthCI	GCNGC	6209919	2113	473
Fnu4HI	GCNGC	6209919	2113	473
ApoI	RAATTY	6382371	2172	460
MjaIV	GTNNAC	6385575	2173	460
BsmAI	GTCTC	6631583	2257	443
Hin4II	CCTTC	7059911	2403	416
NlaIV	GGNNCC	7118874	2423	413
BspKT6I	GATC	7199381	2450	408
BspNCI	CCAGA	7282435	2479	403
HaeIII	GGCC	8562227	2914	343
TspRI	CASTG	8765234	2983	335
HinfI	GANTC	8916048	3035	329
Hpy188I	TCNGA	8942142	3043	329
MboII	GAAGA	9199487	3131	319
BstNI	CCWGG	9855638	3354	298
ScrFI	CCNGG	11805089	4018	249
SsoII	CCNGG	11805089	4018	249
AluI	AGCT	13027766	4434	225
CviAII	CATG	13815688	4702	213
FatI	CATG	13815688	4702	213
NlaIII	CATG	13815688	4702	213
DdeI	CTNAG	14312039	4871	205
MseI	TTAA	19214668	6540	153
MnlI	CCTC	27739484	9442	106

B = C or G or T; **D** = A or G or T; **H** = A or C or T; **K** = G or T;

M = A or C; **N** = A or C or G or T; **R** = A or G; **S** = C or G; **V** = A or C or G; **W** = A or T; **Y** = C or T.

4. Design of Recognition Oligonucleotides

[0067] In the methods provided herein a Recognition Oligonucleotide is hybridized to the immobilized target polynucleotide, thereby forming a recognition-oligonucleotide-target polynucleotide hybrid. Formation of the hybrid allows cleavage by a restriction enzyme and subsequent formation of a free DNA terminus to which a double stranded "adaptor" construct is ligated.

4.1. Structure of Recognition Oligonucleotide

[0068] It will be appreciated that the Recognition Oligonucleotide should be designed taking into account the considerations of §3(a)(ii)-(iv), above, because the Recognition Oligonucleotide and the RE together determine what positions in the cDNA are cleaved.

[0069] The Recognition Oligonucleotide is a single stranded nucleic acid, typically single stranded DNA. The Recognition Oligonucleotide is generally less than 300 bases in length, and more often the Recognition Oligonucleotide is from about 10 to about 90 bases in length. For example, in some embodiments, the Recognition Oligonucleotide is about 15 to about 85 bases in length. In some embodiments, the Recognition Oligonucleotide has a length in the range of 35 to 65 bases; 40 to 60 bases; 15 to 55 bases; 50 to 55 bases; In some embodiments, Recognition Oligonucleotide is about 12, about 15, about 18, about 20, about 22, about 25, about 26, about 28, about 30, about 35, about 40, about 45, about 50, about 55, about 60 bases, about 65 bases, about 70 bases, about 75 bases or about 80 bases in length. In some embodiments, Recognition Oligonucleotide is 26 bases in length.

[0070] In some embodiments the Recognition Oligonucleotide has a sequence exactly complementary to the portion of the sequence of the cDNA to which the Recognition Oligonucleotide hybridizes. However, hybridization between the Recognition Oligonucleotide and immobilized cDNA does not require 100% complementarity. Recognition Oligonucleotide and the immobilized target polynucleotide are hybridizable when there is a sufficient degree of complementarity to avoid non-specific binding of Recognition Oligonucleotide to non-target sequences under conditions where specific binding is desired, for example under conditions that allow for site-specific restriction enzyme digestion. Typically there is exact complementarity at the RE recognition site. In some embodiments, the Recognition Oligonucleotide (i) has the structure 5'-A_n-X_m-B_n-3' where each n is independently an integer from 5-40, X is a RE recognition sequence, and m is an integer from 4 to 10 and (ii) hybridizes to a cDNA sequence the structure 5'-A''-X'-B''-3', wherein A and B are nucleotide sequences complementary or partially complementary to sequence A'' and B'' and X is exactly complementary to X'.

4.2 Degenerate Recognition Oligonucleotides

[0071] In some embodiments the Recognition Oligonucleotide is a library or population of oligonucleotides in which certain positions are completely degenerate (i.e., oligonucleotides with A, T, G and C are represented), partially degenerate (i.e., oligonucleotides with two or three of the bases A, T, G and C are represented), and/or represented by a 'universal' base, such as deoxyinosine) is used.

[0072] Two types of degeneracy may be considered. First, there may be degeneracy at positions in the RE recognition site, to account for REs with more than one cleavage sequence. For example, BaeGI recognizes 5'-GKGCMC-3' where K = G or T and M = A or C. In the case of BaeGI, for illustration and not limitation, the library could contain Recognition Oligonucleotides with four different RE recognition sites: 5'-GGGCAC-3'; 5'-GGGCCC-3'; 5'-GTGCAC-3'; 5'-and GTGCCC-3'.

[0073] The second type of degeneracy is degeneracy in the sequences flanking the RE recognition sites. In one embodiment the flanking sequences are fully degenerate, so that some oligonucleotide

from the library of Recognition Oligonucleotides can hybridize to any cDNA that comprises the appropriate RE recognition site.

4.3. Multiple Recognition Oligonucleotides

[0074] In some embodiments, a library comprises more than one cleaving agent recognition sequence, such as two, three or four different sequences. In embodiments, the different cleaving agent recognition sequences are recognized by different cleaving agents.

4.4 Specific Targets

[0075] In some embodiments, recognition oligonucleotides are selected to bind only one or more particular subsets of sequences. For example, recognition oligonucleotides could be selected so that only cDNAs encoding actin are tagged.

4.5 Sequencing Genomic or Mitochondrial DNA

[0076] It will be recognized that methods, systems and devices described here in the context of characterizing RNA can be used for DNA sequencing, with modifications that will be clear to one of skill in the art guided by this specification (e.g., genomic DNA is fragmented and individual fragments are sequenced, single-stranded DNA is made double-stranded using a DNA-dependent DNA polymerase).

PART 2: AMPLIFICATION AND SEQUENCING TAGGED NUCLEIC ACID SEQUENCES

[0077] Additional processing steps, as shown below, may be used to sequence the tagged molecule.

5.1 Clonal Amplification On Surface

[0078] In certain embodiments, the tagged cDNA templates are amplified prior to sequencing to result in a clonal (bi-clonal, or oligo-clonal) population of template molecules on the surface (e.g. on an individual bead, at a particular position on a surface, etc.). Examples of clonal amplification methods include bridge amplification and wildfire amplification. However, the invention is not limited to any particular method of amplification. Further, amplification is not required. For example, single polynucleotides may be characterized.

[0079] As discussed below, individual tagged cDNA molecules may be amplified to create clusters of copies of the same molecule, an approach useful for certain sequencing methods. In one embodiment, the mRNAs are captured in physically distinct surfaces or areas on a surface (e.g., on beads, in wells, at positions on an array). In an embodiment, the mRNAs are captured so that at least some physically distinct areas capture a single mRNA (e.g., one mRNA per bead, or one mRNA per well). In an embodiment, each some physically distinct area comprises, on average, one mRNA (e.g., on average from 0.5 to 1.5 mRNA molecules per physically distinct area).

5.1.1. Bridge amplification

[0080] **Fig. 10** shows synthesis of the cDNA second strand. The AP1' tag sequence of the first strand hybridizes to **immobilized oligonucleotide** comprising a complementary sequence (AP1) which acts as primer to synthesize the second strand. The well-known process of bridge amplification continues as illustrated in **Figs. 11-13**. **Fig. 12** illustrates the surface after amplification, resulting in clonal templates for sequencing. **Fig. 13** illustrates sequencing by synthesis using a primer

complementary to AP1'. **Fig. 14** illustrates that one of the strands (i.e., the population of forward strands or the population of reverse strands may be removed before sequencing resulting in a lawn of single strands that may be sequenced.

[0081] As described hereinbelow, the steps above may be carried out with a large and heterogeneous mixture of mRNA molecules, such as a population of mRNA molecules from a single cell of a small number of cells.

5.1.2 Wildfire amplification

[0082] "Wildfire" amplification (Ma et al., 2013, Isothermal amplification method for next-generation sequencing" *Proc Nat Acad Sci* 10:14320-23) can be used for solid-phase clonal amplification. See US 2012/0156728 (Wildfire amplification) and US 2013/0203607 (WildFirePaired-End sequencing). In a modification of this approach, illustrated at **Figs. 15-16**, polyadenylated mRNA is hybridized to an immobilized poly(T) sequence, first strand cDNA synthesis is carried out, and the RNA template is removed, leaving an immobilized first strand cDNA. The cDNA is tagged as described above, and then amplified using the Wildfire method.

5.2 Sequencing

[0083] Sequencing of individual molecules (single molecule sequencing) or clonal populations can be carried out using known methods such as Solexa (Illumina) sequencing, pyrosequencing (454), SOLiD sequencing, and Polonator sequencing. See, e.g., Shendure and Ji, 2008, "Next-generation DNA sequencing" *Nature Biotechnology* 26:1135-45, especially Figure 3 and references cited therein. Shendure and said references are incorporated herein by reference in their entirety for all purposes. In some embodiments sequencing-by-synthesis methods are used. In some embodiments the sequencing method is a sequencing-by-synthesis method. In some embodiments, reversible terminators are used.

5.3 Sequencing without clonal amplification

[0084] In some embodiments, mRNA is sequenced directly, or after, or coincident with cDNA synthesis without clonal amplification. See, e.g., Causey et al., US Pat. Pub 20110129827 "Methods For Transcript Analysis"; Ozsolak et al., 2010 "Amplification-free digital gene expression profiling from minute cell quantities" *Nature Methods* 7:619-21; Ozsolak et al., 2011 "Single-molecule direct RNA sequencing without cDNA synthesis" *Wiley Interdiscip Rev RNA*. 2011 Jul-Aug; 2(4): 565-570; Hebenstreit, 2012, "Methods, Challenges and Potentials of Single Cell RNA-seq" *Biology (Basel)*. 1(3):658-667; Saliba et al., 2014, "Single-cell RNA-seq: advances and future challenges," *Nucleic Acids Res.* 42:8845-60.

PART 3: METHODS FOR SEQUENCING AND DATA COLLECTION

6. Sequence Determination

[0085] Highthroughput sequencing methods are known in which a nucleic acid template to be sequenced is immobilized or positioned on a solid support, such as a bead, flow cell surface, semiconductor, or the like. A variety of different sequencing approaches may be used. For sequencing methods in which a fluorescence or other light is detected it is desirable that the different template molecules or clonal populations (e.g., amplification clusters) are physically separated and

arranged so that signals corresponding to different the templates are optically distinguishable. Sequences of tagged nucleic acid molecules of the invention may be determined using such methods. Exemplary approaches for sequencing include sequencing on beads and sequencing on a planar substrate.

6.0. Sequencing on beads

[0086] In some approaches templates on beads are sequenced, including beads comprising clonal populations prepared as described in **Part 1**.

[0087] **Fig. 17** illustrates a different on-chip sequencing using bead-based sequencing reactions. As used herein, beads on which target nucleic acids or their amplification products are, or may be, immobilized are referred to as "sequencing beads." In an embodiment illustrated in **Fig. 17**, one or more pre-sequencing steps (e.g., reverse transcription, cleavage, ligation, amplification) may occur on sequencing beads in a first chamber (shown left) and the sequencing beads may be transported to a second chamber (shown right) for the sequencing reaction and optionally, additional pre-sequencing reactions (e.g., amplification). In this context, "sequencing reaction" refers to the generation and detection of signal (typically detection of visible or fluorescent radiation) that provides nucleic acid sequence information. For example, in the case of Illumina/Solexa type sequencing, bridge amplification would be considered a pre-sequencing step, and could occur in either chamber. In some cases there may be multiple pre-sequencing chambers.

6.1. Use of filler beads to produce optically distinguishable signals

[0088] In the approach illustrated in **Fig. 17**, when the sequencing beads are transported from the first to the second chamber they are 'diluted' by the introduction of "filler beads." Filler beads are "inert," in the sense that template nucleic acids are not immobilized on filler beads, and they do not produce detectable signal during the sequencing process. The effect of the addition of the filler beads is to spatially separate the sequencing beads from each other so that signals from individual sequencing beads are optically distinguishable.

[0089] Generally the sequencing beads and filler beads are roughly spherical. Although a spherical shape is not required, for purposes of simplicity, and not limitation, beads will be referred to as having 'diameters' although beads of other shapes (e.g., having a similar volume as a sphere) are contemplated. Typically the filler beads are smaller than the sequencing beads, for example, having a diameter that is about $1/3^{\text{rd}}$ to $1/40^{\text{th}}$ the diameter of the sequencing beads. In one embodiment, the sequencing beads are about 1 to about 3 microns in diameter (e.g., about 2, such as 2.02 microns) and the filler beads are about 0.05 to about 0.4 microns in diameter (e.g., about 0.3, such as 0.28 microns). For example and not limitation, the ratio of sequencing beads to filler beads in the sequencing chamber may be in the range of $1:10^6$ to $1:10^3$ (numbers of beads) and/or in the range of 1:2 to 1:20 (volume of beads).

[0090] In some embodiments the packing density (the fraction of the total bead volume, or chamber volume, filled by the sequencing beads is in the range of 20% - 85%, such as 40 - 70%, such as 55% - 65%, e.g., about 60%. For illustration, a chamber 1 mm wide and 5 mm long (an area of 5×10^6 square microns) accommodates 1.5 million sequencing beads at 60% packing density.

[0091] In an alternative approach the sequencing steps and the detection steps occur in the same chamber, and filler beads are introduced in to the chamber, diluting and separating the sequencing beads, after at least one pre-sequencing step and before the detection step.

[0092] In one aspect, the invention provides a microfluidic device comprising a first, or "pre-sequencing," chamber (in which one or more pre-sequencing reactions occur) and a second, or "sequencing," chamber (suitable for sequencing and detection reactions) connected by a channel having a dimension large enough to allow the sequencing beads to travel from the first to the second chamber. In an embodiment the channel has no cross-sectional dimension (e.g., diameter, width, depth) smaller than 1 micron (e.g., a diameter 1 micron or greater) and preferably no dimension smaller than 2 microns, more preferably no dimension smaller than 3 microns. In one embodiment the dimensions of the first channel are selected to allow sequencing beads to flow through only, or primarily, in "single-file."

[0093] In some embodiments, filler beads are combined with sequencing beads before they enter the sequencing chamber, as illustrated in the figure. Thus, in one embodiment the device comprises a second microfluidic channel in fluidic communication with (a) the first channel or with the second chamber and (b) with a source of filler beads. The dimensions of the second channel are selected to allow the passage of filler beads and may be smaller than those of the first channel. In alternative embodiments, the filler beads and sequencing beads enter the sequencing chamber (i) through separate ports and/or (ii) at separate times. In one embodiment the filler beads are added first and mixing occurs when the sequencing beads are added.

[0094] **Fig. 18** is a fluorescence image that illustrates detection of fluorescent signal from a chamber showing that signals from individual beads can be distinguished when sequencing beads (or a surrogate) are separated by filler beads. The fluorescent beads have a diameter of 2.02 microns (1.05×10^5 beads/microliter). The filler beads have a diameter of 0.28 microns (3.98×10^9 beads/microliter).

[0095] **Fig. 19** illustrates that it is more difficult, but possible, to distinguish individual sequencing beads in the absence of filler beads (3.14×10^5 beads/microliter).

[0096] The dimensions of the first and second chambers may vary depending on the needs of the operator, sequencing method selected, and the method of signal detection. The size and dimensions of the first chamber will be selected based, in part, on the desired capacity to carry out the pre-amplification steps.

[0097] The size and dimensions of the second (sequencing) chamber will take into account three factors. First, generally the second chamber will be large enough to process the reaction products of the first chamber. That is, the size of the second chamber will tend to increase with the size of the first chamber. Second, the second chamber should be large enough to accommodate the filler beads, when used and/or large enough to allow for physical (and optical) separation of sequencing templates. As will be appreciated, optical separation generally requires that the beads be separated in the X-Y dimensions, rather than simply the Z dimension (where the signal detection is roughly orthogonal or incidental to the X-Y dimension). Simply put, it is difficult, for example, to distinguish

signal from two beads stacked in the Z plane, one above the other or other. The reference to beads that are 'optically distinguishable' captures this fact.

[0098] In one approach, the sequencing chamber accommodates only a single layer of beads. For example, the depth of the sequencing chamber may be close to the diameter of the sequencing beads.

[0099] The surface area (i.e., X-Y dimension) of the chamber may be any suitable area, such as 0.1 mm² to 50 mm². In one approach (e.g., for single cell mRNA sequencing the area may be in the range of 0.3 mm² to 6 mm², assuming about 200,000 to 5 M reads are required for appropriate coverage). In some embodiments the area is in the range 1 – 2 mm² for sequencing mRNA from a single cell.

[0100] If it is assumed there are 100–300 × 10⁵ transcripts per cell at least 1–3 million beads would be required. However, for certain applications fewer reads and fewer beads are required. For example, 200,000 reads are sufficient to differentiate cell phenotype (and possibly detect heterogeneity). AA Pollen et al., Nat Biotechnol. 2014 Oct;32(10):1053-8.

6.2 Minimizing movement of beads in the second chamber

[0101] In some embodiments sequencing beads and filler beads are packed tightly in the second chamber to minimize movement during the sequencing reactions (e.g., during wash steps between sequencing cycles). Movement of beads makes it more computationally challenging to interpret signals.

[0102] In one approach, after sequencing beads and filler beads are introduced into the second chamber, the beads are cross-linked to lock them in place (e.g., by exposure to a chemical or physical agent). In one embodiment only the filler beads are cross-linked to each other. Linkers, cross-linking agents, and cross-linking conditions that do not interfere with the sequencing and detection steps should be used.

[0103] Other ways to minimize bead movement is to introduce beads into nanowells, or immobilize them on a substrate within the chamber.

6.3 Other ways to generate optically distinguishable signals

[0104] As noted above, in one bead based method, the sequencing chamber accommodates only a single layer of beads because the depth of the chamber. In alternative bead-based approaches, (i) beads may be immobilized in spaced compartments or pads on the floor of the chamber; (ii) may be constrained by a ligand-antiligand based interaction with the chamber floor (e.g., an antiligand spotted at separate positions on the chamber floor interacts with a ligand on the bead); (iii) may be constrained by a physical interaction with the floor (for example, the floor may be patterned with negatively charged spots separated by a hydrophobic or inert surface such that nucleic acid-covered beads are immobilized on the separated spots. In some embodiments beads are randomly distributed on the chamber floor at sufficiently low density to achieve optically separated signals. This has the obvious disadvantage of reducing capacity.

[0105] In one approach beads are introduced into a chamber comprising a substrate with at least 10,000 reaction chambers (cavities or wells) sized to accommodate a single bead (e.g., similar to a

PicoTiterPlate™; see International patent publication WO 2005003375). The beads are physically separated in the wells.

6.4 Sequencing modules

[0106] The combination of the first and second chambers, optionally a source of filler beads, and connecting channel(s) may be referred to as a “sequencing module.” As illustrated, cells may be captured, washed, and lysed in the microfluidic device outside the sequencing module, followed by introduction of the cell lysate (or an RNA containing fraction) into the first chamber of the module. First strand cDNA synthesis, cleavage and ligation of the adaptor oligonucleotide may be carried out in the first chamber.

[0107] In one embodiment mRNA and beads are combined before entry into the “first” chamber, for example, RNA may be captured in a bead column or ‘pre-chamber’ and the beads then transferred to the ‘first chamber.’

[0108] As illustrated in **Fig. 20**, amplification and sequencing/imaging may be carried out in the second chamber.

6.5 Embodiments not using beads

[0109] In some embodiments, RNA or DNA templates that are not immobilized on beads are transported into the sequencing chamber and are immobilized on a substantially planar substrate. In embodiments the is glass or PDMS on, or comprised by, the chamber floor. A number of approaches to such immobilization are known and could be adapted to the present invention. In one approach a cell lysate is contacted with a poly d(T) coated surface followed by reverse transcription and cDNA sequencing. **Figs. 21 and 22** show exemplary methods for immobilizing oligonucleotides to a surface and many other methods are known in the art. In an approach RNA is introduced into the chamber containing a lawn of capture oligonucleotides at low enough density that individual RNA molecules (and consequently, clonal populations derived from the RNAs) are physically separated and signals emanating therefrom are optically distinguishable. Methods for making random or ordered arrays of template for sequencing are well known. See, for example, US Pat. Pub. 2013/0116153; C. Adessi et al., Nucleic Acids Res. 2000 Oct 15;28(20):E87; M. Fedurco et al., Nucleic Acids Res. 2006 Feb 9;34(3):e22

[0110] In one embodiment, cell lysis and RNA capture take place in the same chamber.

6.6 Performing multiple cycles

[0111] The sequencing-by-synthesis reaction involves multiple cycles of incorporation of a nucleotide or nucleotide analog and detection of signal. This is typically carried out by introducing reagents into the sequencing chamber at a point in the cycle, and removing the reagents and products prior to the beginning of a subsequent cycle. This is accomplished by introducing reagents, reagent solutions, wash solution, and the like into the chamber, and removing them using standard microfluidic methods. In some embodiments, the microfluidic device is preloaded with sequencing reagents and/or wash solutions prior to sequencing.

6.7 Imaging and Analysis

[0112] Signal from the second chamber can be collected using a camera (e.g., CCD camera) and optical systems developed by Fluidigm Corp. and known in the art. See, e.g., **Fig. 23**. In such embodiments, the material between the camera and the signal origin will be transparent to the signal.

[0113] In other embodiments, signal detection may rely on fiber optic or other sensors associated with a particular bead or well.

PART 4: INTEGRATED MICROFLUIDIC DEVICES

7. Integrated Devices

[0114] **Fig. 20** illustrates one way a sequencing cassette can be integrated into a microfluidic chip. In the approach shown the following steps may be carried out, in which steps 2-9 (and optionally step 1) are carried out in the microfluidic device, and steps 6-9 are carried out in the sequencing module:

TABLE 2

Step	
1	Enrich
2	Load and capture single cells
3	Wash and optionally stain cells
4	Optionally image captured cells
5	Lyse cells
6	Capture mRNA on substrate (e.g., beads)
7	Synthesize cDNA (e.g., cDNA synthesis, cleavage, adaptor ligation)
8	Clonal amplification
9	Sequence (e.g., SBS)
10	Analyse

[0115] It will be recognized that **Fig. 20** and **Table 2** are for illustration and not limitation, and that numerous variations of the process are possible.

7.1 Cell Enrichment

[0116] Cell enrichment may occur within the microfluidic device, “off-chip,” or both. Enrichment parameters include physical properties (e.g., size, deformability, density, charge) and biological properties (e.g., expression of marker proteins).

7.2 Capture of Single Cells

[0117] Capture of single cells may be carried out using a variety of method. In one approach, a single cell capturing microfluidic device having features described in WO-2013/130714 (“Methods, systems, and devices for multiple single-cell capturing and processing using microfluidics”) is used to isolate individual cells, process and sequence nucleic acids. It will be within the ability of one skilled in the art guided by this specification to make certain modifications, if desired, such as, for example, incorporating a sequencing module as described above. In one approach a single cell capturing microfluidic device having features described in WO-2014/144789 (“Methods and devices for analysis of defined multicellular combinations”) is used to isolate individual cells, process and sequence nucleic acids. It will be within the ability of one skilled in the art guided by this specification to make certain modifications, if desired, such as, for example, incorporating a sequencing module as described above. WO-2013/130714 and WO-2014/144789 are incorporated herein by reference for all purposes, including descriptions a microfluidic elements such as channels, pumps, etc.

PART 5: ADDITIONAL FEATURES

8. Additional Features

[0118] This section provides additional description about certain elements described above.

8.1 Anchor polynucleotides

[0119] The anchor polynucleotides provided herein are used to capture mRNA molecules to a solid support. Anchor polynucleotides may therefore include an oligo d(T) primer to capture mRNA molecules. The anchor polynucleotide may further provide means to amplify a target polynucleotide (e.g., cDNA) after it has been tagged with the adapter nucleic acid. The anchor polynucleotide may further include a restriction enzyme recognition sequence to provide means for removal of the immobilized target polynucleotide from the solid support after amplification and/or sequencing. Examples, for illustration and not limitation, of anchor polynucleotides are illustrated in **Fig. 2**. In this embodiment, two anchor polynucleotides attached to a solid support (bead) are shown. One anchor polynucleotide, referred to herein as “first anchor polynucleotide” includes an amplification primer (AP1) and a restriction recognition site (e.g., cut site 1 or CS1). The anchor polynucleotide including an oligo d(T) primer, an amplification primer complementary to AP1 (AP1') and a restriction recognition site (e.g., cut site 2 or CS2) is referred to herein as “second anchor polynucleotide.” Further examples of anchor polynucleotides are illustrated in **Fig. 3**. **Fig. 3** shows a first and a second anchor polynucleotide, wherein a mRNA template is annealed via its polyA tail to the oligo d(T) of the second anchor polynucleotide.

8.2 First anchor polynucleotide

[0120] In embodiments, a first anchor polynucleotide is immobilized on the solid support. In embodiments, the first anchor polynucleotide includes a first amplification nucleic acid sequence and

serves as an amplification primer (also referred to as “amplification primer 1” or “AP1”). In embodiments, the first anchor polynucleotide includes a first release nucleic acid sequence such as a restriction enzyme recognition site (also referred to as “cut site 1” or “CS1”). In embodiments, the first release nucleic acid sequence (e.g., CS1) connects the first amplification nucleic acid sequence (e.g., AP1) to the solid support.

8.3 Second anchor polynucleotide

[0121] In some embodiments a second anchor polynucleotide is immobilized on the solid support. In embodiments, the second anchor polynucleotide includes a second amplification nucleic acid sequence (also referred to as amplification primer 2 or AP2). In embodiments, the second anchor polynucleotide includes a second release nucleic acid sequence such as a restriction enzyme recognition site (also referred to as cut site 2 or CS2). In embodiments, the second release nucleic acid sequence (e.g., CS2) connects the second amplification nucleic acid sequence (e.g., AP2) to the solid support. In embodiments, the second amplification nucleic acid sequence (e.g., AP2) connects the second release nucleic acid sequence (e.g., CS2) to the target polynucleotide capturing sequence (e.g., oligo dTT²⁰). Thus, the single stranded cDNA as provided herein may be immobilized on the solid support by being covalently attached to the deoxy-thymine sequence (e.g., oligo dTT²⁰), wherein the deoxy-thymine sequence is linked to the second amplification nucleic acid sequence (e.g., AP2), which is bound to the solid support through the second release nucleic acid sequence (e.g., CS2).

[0122] As describe above, the target polynucleotide may be a single stranded DNA (e.g., cDNA). Where the target polynucleotide is a cDNA, the target polynucleotide may be linked to the solid support through a second anchor polynucleotide. The second anchor polynucleotide includes a target polynucleotide capturing sequence. In embodiments, the target polynucleotide capturing sequence is a deoxy-thymine sequence, also referred to herein as oligo d(T)₂₀.

[0123] Where the target polynucleotide is an RNA (target ribonucleic acid), the target ribonucleic acid may be immobilized on a solid support through hybridization to a target polynucleotide capturing sequence (e.g., an oligo d(T)₂₀). As described above, the target polynucleotide capturing sequence may form part of a second anchor polypeptide provided herein. Where the target polynucleotide capturing sequence is oligo d(T)₂₀, the target ribonucleic acid hybridizes through its polyadenylated 3' end to the target polynucleotide capturing sequence.

8.4 Adapter nucleic acid

[0124] In the methods provided herein, an adapter nucleic acid sequence is ligated to the cleaved target polynucleotide, thereby forming a tagged nucleic acid sequence. The adapter nucleic acid sequence as provided herein may be any nucleic acid capable of being ligated to the cleaved target polynucleotide (e.g., cDNA). The adapter nucleic acid sequence includes a primer amplification sequence therefore provides for means of amplification of the target polynucleotide. In an embodiment, the adapter nucleic acid includes an amplification primer complement (AP1'), which may be used to anneal to the amplification primer (AP1) of the first anchor polynucleotide, thereby providing the means for amplification of the target polynucleotide by, e.g., bridge PCR.

[0125] In embodiments, the adapter nucleic acid includes an amplification primer complement (AP1'), which may be annealed to an amplification primer (AP1), which is not attached to the solid

support, but added to the reaction solution, thereby allowing for amplification of the target polynucleotide by isothermal template, also referred to herein as wildfire PCR.

[0126] In embodiments, the adapter nucleic acid sequence is a double stranded nucleic acid. In embodiments, the adapter nucleic acid sequence is a single stranded nucleic acid. In embodiments, the adaptor nucleic acid sequence includes a first amplification nucleic acid sequence complement. A first amplification nucleic acid sequence complement is a nucleic acid sequence specifically complementary to the first amplification nucleic acid sequence described above. The terms "first amplification nucleic acid sequence" and "second amplification nucleic acid sequence" as provided herein refer to isolated nucleic acids that recognize a target nucleic acid sequence (first and second amplification nucleic acid sequence complement). The first and second amplification nucleic acid sequences are short nucleic acid molecules, for instance DNA oligonucleotides 10 nucleotides or more in length. A contiguous complementary oligonucleotide (e.g., a first amplification nucleic acid sequence complement or a second amplification nucleic acid sequence complement) may be annealed through hybridization to the first and/or second amplification nucleic acid sequence. The contiguous complementary oligonucleotide may be extended along the target polynucleotide by a DNA polymerase enzyme using PCR or other nucleic-acid amplification methods known in the art, thereby amplifying the target polynucleotide. In embodiments, the first and second amplification nucleic acid sequence are independently about 15, 20, 25, 30 or 50 nucleotides or more in length. In embodiments, the first amplification nucleic acid sequence and the second amplification nucleic acid sequence are independently about 10 to about 100 nucleotides in length. In embodiments, the first amplification nucleic acid sequence and the second amplification nucleic acid sequence are independently about 15 to about 95 nucleotides in length.

[0127] Where the adaptor nucleic acid sequence includes a first amplification nucleic acid sequence complement, the first amplification nucleic acid sequence complement may hybridize to a first amplification nucleic acid sequence. As described above, the first amplification nucleic acid sequence is also referred to herein as amplification primer 1, or AP1 and forms part of a first anchor polynucleotide, which is immobilized to the solid support. In the methods provided herein the first anchor polynucleotide may be covalently bound to the solid support. In embodiments, the first amplification nucleic acid sequence complement is hybridized to the first amplification nucleic acid sequence under conditions allowing for PCR amplification, thereby amplifying the target polynucleotide (i.e. tagged nucleic acid sequence). In embodiments, after the ligating of step (iv) the tagged nucleic acid sequence is contacted with a first amplification nucleic acid sequence under conditions allowing for PCR amplification. In embodiments, the first amplification nucleic acid sequence is at least partially complementary to the first amplification nucleic acid sequence complement. In embodiments, the first amplification nucleic acid is not attached to the solid support. In further embodiments, the first amplification nucleic acid hybridizes to the first amplification nucleic acid.

8.5 Array of tagged polynucleotides

[0128] A person of ordinary skill in the art will immediately recognize that the methods of tagging a nucleic acid sequence as provided herein may be applicable to tag a plurality of nucleic acid

sequences. Where the method provided herein includes tagging a plurality of nucleic acid sequences, each of the target polynucleotides may be independently different. Therefore, the target polynucleotides may be heterogeneous. In embodiments, the plurality of target polynucleotides is a plurality of cDNA sequences. In embodiments, the plurality of target polynucleotides is a plurality of ribonucleic acid sequences. The plurality of target polynucleotides may be derived from an isolated cell. An isolated cell as provided herein is a cell that has been substantially separated or purified away from other components (cells) in a cell culture, tissue, organ or organism in which the cell previously occurred. Cells that have been "isolated" include cells purified by standard purification methods.

[0129] In one aspect, a method of forming a plurality of tagged heterogeneous polynucleotides, is provided. According to the method (i) a plurality of heterogeneous target polynucleotides is immobilized on a solid support, thereby forming a plurality of immobilized heterogeneous target polynucleotides. (ii) A plurality of heterogeneous recognition-oligonucleotides is hybridized to the immobilized heterogeneous target polynucleotides, thereby forming a plurality of recognition-oligonucleotide-target polynucleotide hybrids. (iii) The recognition-oligonucleotide-target polynucleotide hybrids are cleaved with a cleaving agent, thereby forming a plurality of cleaved recognition-oligonucleotide-cleaved target polynucleotide hybrids. (iv) An adapter nucleic acid sequence is ligated to the plurality of cleaved target polynucleotides, thereby forming a plurality of tagged heterogeneous polynucleotides. As described above the same definitions apply to the aspects of forming a plurality of tagged heterogeneous polynucleotides including embodiments, thereof. For example, the solid support may be a bead structure. The plurality of heterogeneous target polynucleotides may be single stranded cDNA sequences. The cleaving agent may be a restriction enzyme.

8.6 Embodiments of cDNA tagging

[0130] As described above the target polynucleotide may be a cDNA. Thus, in one aspect a method of forming a tagged single stranded cDNA is provided. According to the method (i) a target cDNA is immobilized on a solid support, thereby forming an immobilized target cDNA. (ii) A recognition-oligonucleotide is hybridized to the immobilized target cDNA, thereby forming a recognition-oligonucleotide-cDNA hybrid. (iii) The recognition-oligonucleotide-cDNA hybrid is cleaved with a cleaving agent, thereby forming a cleaved recognition-oligonucleotide-cleaved cDNA hybrid. (iv) An adapter nucleic acid is ligated to the cleaved cDNA, thereby forming a tagged single stranded cDNA. Where the target polynucleotide is a cDNA, the cDNA may be immobilized on the solid support using immobilization methods commonly known in the art and as described above. For example, the cDNA may be directly immobilized to a chemically modified (functionalized) solid support by covalent attachment. In other embodiments, the cDNA is attached to the solid support through a second anchor polynucleotide as described above. Where the cDNA is attached to the solid support through a second anchor polynucleotide, an mRNA molecule is hybridized on a solid support by hydrogen bonding between the polyadenylated 3' end of the mRNA and the nucleic acid sequence of a target polynucleotide capturing sequence (e.g., deoxy-thymine sequence or oligo dTT²⁰), thereby forming an immobilized mRNA. As described above the target polynucleotide capturing sequence

may form part of a second anchor polypeptide. The immobilized mRNA is subsequently reverse transcribed, thereby forming an RNA:DNA hybrid. The mRNA of the RNA:DNA hybrid may be degraded by contacting the hybrid with an endoribonuclease enzyme (e.g., RNase H), thereby forming a single stranded cDNA attached on a solid support through a target polynucleotide capturing sequence. The immobilized single stranded cDNA (target cDNA) may be hybridized to a recognition-oligonucleotide as described above, thereby forming a recognition-oligonucleotide-cDNA hybrid. As described above Recognition Oligonucleotide may include a cleaving agent recognition sequence (e.g. a BaeG1 recognition sequence) flanked by degenerate nucleic acid sequences. The recognition-oligonucleotide-cDNA hybrid may be cleaved with a cleaving agent (e.g., BaeG1), thereby forming a cleaved recognition-oligonucleotide-cleaved cDNA hybrid. As described above the cleaved recognition-oligonucleotide-cleaved cDNA hybrid may include a 5' overhang. An adapter nucleic acid as described above is ligated to the cleaved cDNA, thereby forming a tagged single stranded cDNA. Any ligation method and DNA ligase commonly known in the art may be used to ligate the adapter nucleic acid to the cleaved cDNA.

8.7 Embodiments of RNA tagging

[0131] As described above the target polynucleotide may be a ribonucleic acid. Thus, in another aspect, a method of forming a tagged nucleic acid sequence is provided. According to the method (i) a target ribonucleic acid is immobilized on a solid support, thereby forming an immobilized target ribonucleic acid. (ii) The immobilized target ribonucleic acid is reverse transcribed, thereby forming an RNA:DNA hybrid. (iii) The RNA:DNA hybrid is cleaved with an RNA:DNA cleaving agent, thereby forming a cleaved RNA:DNA hybrid. (iv) An adapter nucleic acid sequence is ligated to the cleaved RNA:DNA hybrid. (v) The ribonucleic acid sequence is removed from the RNA:DNA hybrid, thereby forming a tagged nucleic acid sequence. Where a target ribonucleic acid is immobilized on a solid support, the target ribonucleic acid may be an mRNA and the immobilization may be performed as described above through hydrogen bonding between the polyadenylation sequence of the mRNA and the polynucleotide capturing sequence described herein. By reverse transcription of the mRNA an RNA:DNA hybrid is formed and the RNA:DNA hybrid may be cleaved using a cleaving agent. The cleaving agent may be a restriction endonuclease capable of cleaving double-stranded hybrids of DNA and RNA, wherein one strand is a DNA and the other strand is a RNA. Upon cleavage of the RNA:DNA hybrid a 5' overhang, 3' overhang or blunt ends without overhang may be generated. Therefore, the cleaved RNA:DNA hybrid may include a 5' overhang, 3' overhang or blunt ends and may subsequently be ligated to an adapter nucleic acid. Once the adapter nucleic acid has been ligated to the RNA:DNA hybrid, the RNA may be removed by digestion using an endoribonuclease as described above, resulting in the formation of a tagged nucleic acid sequence.

[0132] A person of ordinary skill in the art will immediately recognize that the methods of tagging a nucleic acid sequence as provided herein may be applicable to tag a plurality of nucleic acid sequences. Thus, in another aspect a method of forming a plurality of tagged heterogeneous nucleic acid sequences is provided. According to the method (i) a plurality of heterogeneous target ribonucleic acid sequences are immobilized on a solid support, thereby forming a plurality of immobilized heterogeneous target ribonucleic acid sequences. (ii) The immobilized heterogeneous

target ribonucleic acid sequences are reverse transcribed, thereby forming a plurality of heterogeneous RNA:DNA hybrids. (iii) The plurality of heterogeneous RNA:DNA hybrids are cleaved with an RNA:DNA cleaving agent, thereby forming a plurality of cleaved RNA:DNA hybrids. (iv) An adapter nucleic acid sequence is ligated to the plurality of cleaved RNA:DNA hybrids and (v) the ribonucleic acid sequences are removed from the cleaved RNA:DNA hybrids, thereby forming a plurality of tagged heterogeneous nucleic acid sequences.

8.8 Recognition-Oligonucleotide Libraries

[0133] In another aspect, a library of recognition-oligonucleotides including a plurality of heterogeneous recognition-oligonucleotides each including a restriction enzyme recognition sequence flanked by degenerate nucleic acid sequences is provided. The degenerate nucleic acid sequences as provided herein flank the restriction enzyme recognition sequence (also referred to herein as cleaving agent recognition sequence) and include degenerate nucleotides. The degenerate nucleotides may be complementary or partially complementary to different target polynucleotides (e.g. single stranded cDNA). The term "partially complementary" refers to a recognition-oligonucleotide which is capable of hybridizing to more than target polynucleotide, wherein each target polynucleotide is different. In embodiments, the cleaving agent recognition sequence is flanked by degenerate nucleic acid sequences. In embodiments, the degenerate nucleic acid sequences are partially complementary to a target polynucleotide (e.g., a cDNA). In embodiments, the degenerate nucleic acid sequences are specifically complementary to a target polynucleotide. In embodiments, the recognition-oligonucleotides have a structure of 5' A_n-X_m-B_n 3', wherein A and B are nucleotide sequences complementary or partially complementary to a sequence comprised by a target polynucleotide and n is independently an integer from 10-40. X is a cleaving agent recognition sequence and m is an integer from 4 to 10. The cleaving agent may be a restriction enzyme as described above (e.g., BaeG1). In embodiments, the library forms part of a microfluidic device.

8.9 PCR Amplification

[0134] The tagged polynucleotides provided herein may be amplified and subsequently sequenced. Any nucleic acid amplification method known in the art may be used. In one specific, non-limiting example, polymerase chain reaction (PCR) is used to amplify the tagged polynucleotides provided herein. In embodiments, the tagged polynucleotides provided herein are amplified using bridge PCR. Thus, in embodiments, the PCR amplification is bridge PCR. The technique of bridge PCR is well known in the art and has been described for example in published international application WO2013/131962 A1, which is hereby incorporated by reference in its entirety and for all purposes. In embodiments, the tagged polynucleotides provided herein are amplified using isothermal template walking. Thus, in embodiments, the PCR amplification is isothermal template walking. Isothermal template walking is an amplification method well known in the art and is described for example by Ma Z *et al.*, PNAS 2013;110:14320-14323, which is hereby incorporated by reference in its entirety and for all purposes. In embodiments, the method includes after the contacting of step sequencing the amplified cDNA. In embodiments, each step occurs in a microfluidic device. Examples of a microfluidic device useful for the invention provided are disclosed in published US application number US2013/0302883, US2013/0302884, US2013/0296196,

US2013/0295602, and US2013/0302807, which are hereby incorporated by reference in their entirety and for all purposes.

[0135] In another aspect, a method of amplifying a cDNA sequence is provided. According to the method (i) an RNA molecule extracted from an isolated cell is immobilized on a solid support, thereby forming an immobilized ribonucleic acid sequence. (ii) The immobilized ribonucleic acid sequence is reverse transcribed, thereby forming an immobilized RNA:DNA hybrid. (iii) The ribonucleic acid sequence is removed from the RNA:DNA hybrid, thereby forming an immobilized cDNA sequence. (iv) A recognition-oligonucleotide is hybridized to the immobilized cDNA sequence, thereby forming a recognition- oligonucleotide-cDNA hybrid. (v) The recognition- oligonucleotide-cDNA hybrid is cleaved with a cleaving agent, thereby forming a cleaved recognition- oligonucleotide-cleaved cDNA hybrid. (vi) An adapter nucleic acid sequence is ligated to the cleaved cDNA, thereby forming a tagged cDNA sequence. (vii) The tagged cDNA sequence is hybridized to an amplification nucleic acid sequence under conditions allowing for PCR amplification, thereby amplifying a cDNA sequence. In embodiments, amplification nucleic acid sequence is covalently bound to the solid support. In embodiments, the amplified cDNA is sequenced after the hybridizing of step (vii). Any sequencing method known in the art may be used for sequencing the amplified cDNA

[0136] In another aspect, a method of amplifying a cDNA sequence is provided. According to the method (i) an RNA molecule extracted from an isolated cell is immobilized on a solid support, thereby forming an immobilized ribonucleic acid sequence. (ii) The immobilized ribonucleic acid sequence is reversed transcribed, thereby forming an immobilized RNA:DNA hybrid. (iii) The RNA:DNA hybrid is cleaved with an RNA:DNA cleaving agent, thereby forming a cleaved RNA:DNA hybrid. (iv) An adapter nucleic acid sequence is ligated to the cleaved RNA:DNA hybrid. (v) The ribonucleic acid is removed from the cleaved RNA:DNA hybrid, thereby forming a tagged cDNA sequence and (vi) the tagged cDNA sequence is contacted with an amplification nucleic acid sequence under conditions allowing for PCR amplification, thereby amplifying said cDNA sequence. In embodiments, the amplification nucleic acid sequence is covalently bound to the solid support (e.g. AP1). In embodiments, the amplified cDNA is sequenced after the contacting of step (vi). In embodiments, the PCR amplification is PCR bridge amplification. In embodiments, the PCR amplification is isothermal template walking. In embodiments, the single cell is isolated from a heterogeneous population of isolated cells. In embodiments, each step of the methods provided herein occurs in a microfluidic device.

* * * * *

[0137] While the foregoing invention has been described in some detail for purposes of clarity and understanding, it will be appreciated by those skilled in the relevant arts, once they have been made familiar with this disclosure, that various changes in form and detail can be made without departing from the true scope of the invention in the appended claims. The invention is therefore not to be limited to the exact components or details of methodology or construction set forth above. Except to the extent necessary or inherent in the processes themselves, no particular order to steps or stages of methods or processes described in this disclosure, including the Figures, is intended or implied. In many cases the order of process steps may be varied without changing the purpose, effect, or import of the methods described.

[0138] All publications and patent documents cited herein are incorporated herein by reference as if each such publication or document was specifically and individually indicated to be incorporated herein by reference. Citation of publications and patent documents (patents, published patent applications, and unpublished patent applications) is not intended as an admission that any such document is pertinent prior art, nor does it constitute any admission as to the contents or date of the same.

WHAT IS CLAIMED IS:

1. A method of forming a tagged nucleic acid sequence, said method comprising:
 - (i) immobilizing a target polynucleotide on a solid support, thereby forming an immobilized target polynucleotide;
 - (ii) hybridizing a recognition-oligonucleotide to said immobilized target polynucleotide, thereby forming a recognition-oligonucleotide-target polynucleotide hybrid;
 - (iii) cleaving said recognition-oligonucleotide-target polynucleotide hybrid with a cleaving agent, thereby forming a cleaved recognition-oligonucleotide-cleaved target polynucleotide hybrid comprising a cleaved target polynucleotide; and
 - (iv) ligating an adapter nucleic acid sequence to said cleaved target polynucleotide, thereby forming a tagged nucleic acid sequence
2. The method of the preceding claim, wherein said immobilizing of step (i) comprises:
 - (a) capturing an RNA molecule to a solid support, thereby forming a captured RNA; and
 - (b) reverse transcribing said captured RNA, thereby forming a target polynucleotide immobilized to said solid support.
3. The method of either preceding claim, wherein said target polynucleotide is a single stranded cDNA.
4. The method of any preceding claim, wherein said solid support comprises a bead structure.
5. The method of claim 4, wherein said bead structure is a biotin bead.
6. The method of any preceding claim, wherein a first anchor polynucleotide is covalently bound to said solid support.
7. The method of claim 6, wherein said first anchor polynucleotide comprises a first amplification nucleic acid sequence.
8. The method of claim 7, wherein said first anchor polynucleotide further comprises a first release nucleic acid sequence.
9. The method of claim 8, wherein said first release nucleic acid sequence connects said first amplification nucleic acid sequence to said solid support.

10. The method of claim 9 or claim 10, wherein said first release nucleic acid sequence comprises a restriction enzyme cleavage sequence.
11. The method of claim 3, wherein said cDNA is linked to said solid support through a second anchor polynucleotide.
12. The method of claim 11, wherein said second anchor polynucleotide comprises a target polynucleotide capturing sequence.
13. The method of claim 12, wherein said target polynucleotide capturing sequence is a deoxy-thymine sequence.
14. The method of claim 12 or claim 13, wherein said second anchor polynucleotide further comprises a second amplification nucleic acid sequence.
15. The method of any of claims 12 to 14, wherein said second anchor polynucleotide further comprises a second release nucleic acid sequence.
16. The method of claim 15, wherein said second release nucleic acid sequence connects said second amplification nucleic acid sequence to said solid support.
17. The method of claim 16, wherein said second amplification nucleic acid sequence connects said second release nucleic acid sequence to said target polynucleotide capturing sequence.
18. The method of any of claims 15 to 17, wherein said second release nucleic acid sequence is a restriction enzyme cleavage sequence.
19. The method of any preceding claim, wherein said recognition-oligonucleotide comprises a cleaving agent recognition sequence.
20. The method of claim 19, wherein said cleaving agent recognition sequence is flanked by degenerate nucleic acid sequences.
21. The method of claim 20, wherein said degenerate nucleic acid sequences are at least partially complementary to said target polynucleotide.
22. The method of claim 19, wherein said cleaving agent is a restriction enzyme.

23. The method of any preceding claim, wherein said adaptor nucleic acid sequence comprises a first amplification nucleic acid sequence complement.

24. The method of claim 23, comprising hybridizing said first amplification nucleic acid sequence complement to said first amplification nucleic acid sequence under conditions allowing for PCR amplification, thereby amplifying said tagged nucleic acid sequence.

25. The method of any preceding claim, further comprising after said ligating of step (iv) contacting said tagged nucleic acid sequence with a first amplification nucleic acid sequence under conditions allowing for PCR amplification.

26. The method of claim 23, wherein said amplification nucleic acid sequence is at least partially complementary to said first amplification nucleic acid sequence complement.

27. A method of forming a plurality of tagged heterogeneous polynucleotides, said method comprising:

(i) immobilizing a plurality of heterogeneous target polynucleotides on a solid support, thereby forming a plurality of immobilized heterogeneous target polynucleotides;

(ii) hybridizing a plurality of heterogeneous recognition-oligonucleotides to said immobilized heterogeneous target polynucleotides, thereby forming a plurality of recognition-oligonucleotide-target polynucleotide hybrids;

(iii) cleaving said recognition-oligonucleotide-target polynucleotide hybrids with a cleaving agent, thereby forming a plurality of cleaved recognition-oligonucleotide-cleaved target polynucleotide hybrids; and

(iv) ligating an adapter nucleic acid sequence to said plurality of cleaved target polynucleotides, thereby forming a plurality of tagged heterogeneous polynucleotides.

28. The method of claim 27, wherein said solid support comprises a bead structure.

29. The method of claim 27 or claim 28, wherein said plurality of heterogeneous target polynucleotides are single stranded cDNA sequences.

30. The method of any of claims 27 to 29, wherein said cleaving agent is a restriction enzyme.

31. A method of forming a tagged single stranded cDNA, said method comprising:

(i) immobilizing a target cDNA on a solid support, thereby forming an immobilized target cDNA;

(ii) hybridizing a recognition-oligonucleotide to said immobilized target cDNA, thereby forming a recognition-oligonucleotide-cDNA hybrid;

(iii) cleaving said recognition-oligonucleotide-cDNA hybrid with a cleaving agent, thereby forming a cleaved recognition-oligonucleotide-cleaved cDNA hybrid; and

(iv) ligating an adapter nucleic acid to said cleaved cDNA, thereby forming a tagged single stranded cDNA.

32. A method of forming a tagged nucleic acid sequence, said method comprising:

(i) immobilizing a target ribonucleic acid on a solid support, thereby forming an immobilized target ribonucleic acid (RNA);

(ii) synthesizing a complementary DNA (cDNA) strand, thereby forming an RNA:cDNA hybrid;

(iii) cleaving the RNA:cDNA hybrid with an RNA:cDNA cleaving agent, to generate a cleaved RNA:cDNA hybrid, wherein the cDNA comprises a ligatable end;

(iv) ligating an adapter oligonucleotide to the ligatable end ; and

(v) removing the ribonucleic acid sequence from said RNA:cDNA hybrid, thereby forming a tagged nucleic acid sequence.

33. A method of forming a plurality of tagged heterogeneous nucleic acid sequences, said method comprising:

(i) immobilizing a plurality of heterogeneous target ribonucleic acid sequences on a solid support, thereby forming a plurality of immobilized heterogeneous target ribonucleic acid sequences;

(ii) reverse transcribing said immobilized heterogeneous target ribonucleic acid sequences, thereby forming a plurality of heterogeneous RNA:DNA hybrids;

(iii) cleaving said plurality of heterogeneous RNA:DNA hybrids with an RNA:DNA cleaving agent, thereby forming a plurality of cleaved RNA:DNA hybrids;

(iv) ligating an adapter nucleic acid sequence to said plurality of cleaved RNA:DNA hybrids; and

(v) removing said ribonucleic acid sequences from said cleaved RNA:DNA hybrids, thereby forming a plurality of tagged heterogeneous nucleic acid sequences.

34. A library of recognition-oligonucleotides comprising a plurality of heterogeneous recognition-oligonucleotides each comprising a restriction enzyme recognition sequence flanked by degenerate nucleic acid sequences.

35. The library of claim 34, wherein said cleaving agent is a restriction enzyme, and/or said library forms part of a microfluidic device.

36. The library of claim 34 or 35, configured for use in the method of any of claims 1 to 33.

37. A method of amplifying a cDNA sequence, said method comprising:

(i) immobilizing an RNA molecule extracted from an isolated cell on a solid support, thereby forming an immobilized ribonucleic acid sequence;

(ii) reverse transcribing said immobilized ribonucleic acid sequence, thereby forming an immobilized RNA:DNA hybrid;

(iii) removing said ribonucleic acid sequence from said RNA:DNA hybrid, thereby forming an immobilized cDNA sequence;

(iv) hybridizing a recognition oligonucleotide to said immobilized cDNA sequence, thereby forming a recognition- oligonucleotide:DNA hybrid;

(v) cleaving said recognition oligonucleotide:cDNA hybrid with a cleaving agent, thereby forming a cleaved recognition oligonucleotide:cleaved cDNA hybrid;

(vi) ligating an adapter nucleic acid sequence to said cleaved cDNA, thereby forming a tagged cDNA sequence;

(vii) hybridizing said tagged cDNA sequence to an amplification nucleic acid sequence under conditions allowing for PCR amplification, thereby amplifying a cDNA sequence.

38. The method of claim 37, wherein said amplification nucleic acid sequence is covalently bound to said solid support.

39. The method of claim 37 or 38, further comprising after said hybridizing of step (vii) sequencing said amplified cDNA.

40. A method of amplifying a cDNA sequence, said method comprising:

(i) immobilizing an RNA molecule extracted from an isolated cell on a solid support, thereby forming an immobilized ribonucleic acid sequence;

(ii) reverse transcribing said immobilized ribonucleic acid sequence, thereby forming an immobilized RNA:DNA hybrid;

(iii) cleaving said RNA:DNA hybrid with an RNA:DNA cleaving agent, thereby forming a cleaved RNA:DNA hybrid;

(iv) ligating an adapter nucleic acid sequence to said cleaved RNA:DNA hybrid;

(v) removing said ribonucleic acid from said cleaved RNA:DNA hybrid, thereby forming a tagged cDNA sequence; and

(vi) contacting said tagged cDNA sequence with an amplification nucleic acid sequence under conditions allowing for PCR amplification, thereby amplifying said cDNA sequence.

41. The method of claim 40, wherein said amplification nucleic acid sequence is covalently bound to said solid support.

42. The method of claim 40 or 41, further comprising after said contacting of step (vi) sequencing said amplified cDNA.

43. The method of claim 37 or 40, wherein said PCR amplification is PCR bridge amplification.

44. The method of claim 37 or 40, wherein said PCR amplification is isothermal template walking.

45. The method of any of claims 39-44, comprising isolating said single cell from a heterogeneous population of isolated cells.

46. The method of any of claims 1-33 or 37-45, wherein each step is performed in a microfluidic device.

1 / 23

FRAGMENTATION OF RNA:DNA HYBRID (PT)




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6A




FIG. 6B





FIG. 7

8 / 23

Fragmentation of DNA:DNA hybrid

Sequencing
prep

- First strand synth.
- Fragmentation (3' end counting)
- Adapter ligation
- Solid phase clonal amplification

**FIG. 8**

9 / 23



Contd: DNA:DNA hybrid

FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15

Starting Wildfire from mRNA




FIG. 16




FIG. 17

18 / 23




FIG. 18




FIG. 19

Chemistry Process Integration

Bead based Sequencing Chemistry could facilitate on-chip integration





FIG. 20

mRNA capture		Surface functionalization POC			
	Chemistry	Surface treatment	5' oligo modification	Cross-linker/Activator	
1	Isothiocyanate	Aminopropyl-tri ethoxy silane	Amine	1,4 Phenylene diisothiocyanate	
2	Epoxide	Epoxy silane	Amine	None	
3	Thiol	Aminopropyl-tri ethoxy silane	Thiol	s-MBS (m-maleimidobenzoyl-N-hydroxysuccinimide ester)	
4	Phosphorothioate	Derivatized acrylamide gel: BRAPA (N-5-bromoacetamidylpentyl) acrylamide X	Phosphorothioate (PS)	None	
		X 2% acrylamide gel with BRAPA, TEMED, & potassium persulfate			

FIG. 21

22
IN
 G
 L




FIG. 23

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2015/029986

A. CLASSIFICATION OF SUBJECT MATTER

C12Q 1/68 (2006.01)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

DATABASES: TXPEA, TXPEB, TXPEC, TXPEE, TXPEF, TXPEF, TXPEI, TXPEP, TXPEPEA, TXPES, TXPUS01A, TXPUSE1A, TXPUSEA, TXPUSEB, TXPW0EA, WPIAP, EPODOC, MEDLINE, BIOSIS, HCAPLUS, EMBASE with KEYWORDS: tagged, barcode, adaptor, ligate, ligase, oligonucleotide, primer, single cell, microfluidic, high throughput, immobilised, bead, solid support, restriction endonuclease & like terms. DATABASES: AusPat, The Lens, Google, PAMS NOSE, INTESS with Applicant / Inventor names.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	Documents are listed in the continuation of Box C	

☒ Further documents are listed in the continuation of Box C

☒ See patent family annex

* "A"	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier application or patent but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search 6 July 2015		Date of mailing of the international search report 06 July 2015	
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA Email address: pct@ipaustalia.gov.au		Authorised officer Catriona Bruce AUSTRALIAN PATENT OFFICE (ISO 9001 Quality Certified Service) Telephone No. +61 2 6283 7940	

INTERNATIONAL SEARCH REPORT		International application No.
C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		PCT/US2015/029986
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SCHLAGER, J. J., et al., 'A degenerative primer set for PCR amplification of murine immunoglobulin heavy chain', Abstract, Medical Defense Bioscience Review, Proceedings, Baltimore, May 12-16, 1996, Volume 3, pages 1582-1589. Publisher: National Technical Information Service, Springfield, Virginia, USA Abstract	1-46
A	WO 2002/018629 A1 (MACQUARIE RESEARCH LTD) 07 March 2002 Abstract; Figure 3B	1-46
A	WO 2002/046449 A2 (THE PENNSYLVANIA STATE UNIVERSITY) 13 June 2002 Abstract; Claims	1-46
A	WO 1998/015652 A1 (BRAX GENOMICS LIMITED) 16 April 1998 Abstract; Claims; pages 2-3	1-46
A	WO 1999/002727 A1 (BRAX GENOMICS LIMITED) 21 January 1999 Abstract	1-46
A	WO 2012/162267 A2 (FLUIDIGM CORPORATION) 29 November 2012 Abstract; Figure 2; para [0328]	1-46

Form PCT/ISA/210 (fifth sheet) (July 2009)

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
the subject matter listed in Rule 39 on which, under Article 17(2)(a)(i), an international search is not required to be carried out, including
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

See Supplemental Box for Details

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

Supplemental Box**Continuation of: Box III**

This International Application does not comply with the requirements of unity of invention because it does not relate to one invention or to a group of inventions so linked as to form a single general inventive concept.

This Authority has found that there are different inventions based on the following features that separate the claims into distinct groups:

- Claims 1-31, 37-39 (partially) are directed to methods of tagging and amplifying nucleic acid sequences. The feature of methods of tagging and amplifying nucleic acid sequences, wherein a nucleic acid is immobilized and then annealed to a recognition oligonucleotide comprising a restriction endonuclease recognition site, which is then cleaved and the product ligated to an tagged adaptor oligonucleotide that allows amplification using primers specific for sequences present in both the recognition and adaptor oligonucleotides. is specific to this group of claims.
- Claims 32-33, 40-46 are directed to methods of tagging and amplifying nucleic acid sequences. The feature of methods of tagging and amplifying nucleic acid sequences, wherein ribonucleic acid is immobilized and then an RNA:cDNA hybrid is synthesised, which is then cleaved and the product ligated to an tagged adaptor oligonucleotide that allows amplification using primers specific for sequences present in both the recognition and adaptor oligonucleotides. is specific to this group of claims.
- Claims 34-36 (entirely) and 1-31, 37-39 (partially) are directed to libraries of oligonucleotides. The feature of libraries of recognition oligonucleotides comprising restriction enzyme recognition sequence flanked by degenerate nucleic acid sequences is specific to this group of claims.

PCT Rule 13.2, first sentence, states that unity of invention is only fulfilled when there is a technical relationship among the claimed inventions involving one or more of the same or corresponding special technical features. PCT Rule 13.2, second sentence, defines a special technical feature as a feature which makes a contribution over the prior art.

When there is no special technical feature common to all the claimed inventions there is no unity of invention.

In the above groups of claims, the identified features may have the potential to make a contribution over the prior art but are not common to all the claimed inventions and therefore cannot provide the required technical relationship. Therefore there is no special technical feature common to all the claimed inventions and the requirements for unity of invention are consequently not satisfied *a priori*.

INTERNATIONAL SEARCH REPORT		International application No.	
Information on patent family members		PCT/US2015/029986	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
WO 2002/018629 A1	07 March 2002	AU 8371001 A	13 Mar 2002
		AU 2001283710 B2	22 Jul 2004
		EP 1320630 A1	25 Jun 2003
		EP 1320630 B1	21 Oct 2009
		JP 2004506450 A	04 Mar 2004
		US 2004053267 A1	18 Mar 2004
		US 7771974 B2	10 Aug 2010
WO 2002/046449 A2	13 June 2002	AU 778737 B2	16 Dec 2004
		AU 2875602 A	18 Jun 2002
		AU 4247200 A	14 Nov 2000
		AU 5347101 A	30 Oct 2001
		AU 2001253471 B2	26 Jul 2007
		CA 2365901 A1	19 Oct 2000
		CA 2406403 A1	25 Oct 2001
		CA 2436519 A1	13 Jun 2002
		EP 1169480 A1	09 Jan 2002
		EP 1353935 A2	22 Oct 2003
		EP 1397489 A2	17 Mar 2004
		EP 1702983 A2	20 Sep 2006
		JP 2002541822 A	10 Dec 2002
		JP 2004525602 A	26 Aug 2004
		US 6271359 B1	07 Aug 2001
		US 2005107326 A1	19 May 2005
		US 7575918 B2	18 Aug 2009
		US 2004209263 A1	21 Oct 2004
		US 2004220123 A1	04 Nov 2004
		US 2006223774 A1	05 Oct 2006
		WO 0061804 A1	19 Oct 2000
		WO 0179524 A2	25 Oct 2001
WO 1998/015652 A1	16 April 1998	AU 725966 B2	26 Oct 2000
		AU 728805 B2	18 Jan 2001
		AU 732455 B2	26 Apr 2001
		AU 746719 B2	02 May 2002
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.			
Form PCT/ISA/210 (Family Annex)(July 2009)			

INTERNATIONAL SEARCH REPORT		International application No.	
Information on patent family members		PCT/US2015/029986	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
		AU 4921099 A	01 Feb 2000
		AU 769966 B2	12 Feb 2004
		AU 772514 B2	29 Apr 2004
		AU 772593 B2	29 Apr 2004
		AU 1770499 A	12 Jul 1999
		AU 2536899 A	15 Sep 1999
		AU 4566397 A	05 May 1998
		AU 4920399 A	01 Feb 2000
		AU 4920499 A	01 Feb 2000
		AU 5570098 A	07 Aug 1998
		AU 5570298 A	07 Aug 1998
		AU 7342898 A	27 Nov 1998
		BG 104705 A	30 Apr 2001
		BR 9908155 A	31 Oct 2000
		CA 2277520 A1	23 Jul 1998
		CA 2277786 A1	23 Jul 1998
		CA 2288789 A1	12 Nov 1998
		CA 2317416 A1	02 Sep 1999
		CA 2337207 A1	20 Jan 2000
		CA 2337761 A1	20 Jan 2000
		CA 2337762 A1	20 Jan 2000
		CA 2385962 A1	20 Jan 2000
		CA 2385970 A1	20 Jan 2000
		CA 2385987 A1	20 Jan 2000
		CA 2441655 A1	23 Jul 1998
		CN 1250483 A	12 Apr 2000
		CN 1291194 A	11 Apr 2001
		CO 5011102 A1	28 Feb 2001
		DZ 2644 A1	15 Mar 2003
		EA 002824 B1	31 Oct 2002
		EE 200000514 A	15 Feb 2002
		EP 0960215 A1	01 Dec 1999
		EP 0979305 A1	16 Feb 2000
		EP 0979305 B1	27 Sep 2006
		EP 0986562 A1	22 Mar 2000
		EP 0986562 B1	07 Aug 2002
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.			

INTERNATIONAL SEARCH REPORT		International application No.	
Information on patent family members		PCT/US2015/029986	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
		EP 1042345 A1	11 Oct 2000
		EP 1042345 B1	16 Apr 2003
		EP 1070066 A1	24 Jan 2001
		EP 1095051 A1	02 May 2001
		EP 1095052 A1	02 May 2001
		EP 1095053 A1	02 May 2001
		EP 1095053 B1	11 Dec 2002
		EP 1275655 A1	15 Jan 2003
		EP 1400599 A1	24 Mar 2004
		EP 1400599 B1	03 Oct 2007
		GB 2340122 A	16 Feb 2000
		GB 2340237 A	16 Feb 2000
		GB 2340237 B	08 Oct 2003
		GB 2340602 A	23 Feb 2000
		HR P980584 A2	31 Oct 1999
		HR P20000555 A2	31 Aug 2001
		HU 0100647 A2	28 Sep 2001
		IL 130885 A	17 May 2005
		IL 130886 A	19 Feb 2004
		IS 5575 A	25 Jul 2000
		JP 2002520580 A	09 Jul 2002
		JP 3692299 B2	07 Sep 2005
		JP 2001508307 A	26 Jun 2001
		JP 3884087 B2	21 Feb 2007
		JP 2001525802 A	11 Dec 2001
		JP 4672820 B2	20 Apr 2011
		JP 2001508308 A	26 Jun 2001
		JP 2002504554 A	12 Feb 2002
		JP 2002520329 A	09 Jul 2002
		JP 2002520330 A	09 Jul 2002
		JP 2004357697 A	24 Dec 2004
		JP 2006208400 A	10 Aug 2006
		NO 20004242 A	24 Aug 2000
		NZ 336769 A	26 Jan 2001
		NZ 336770 A	26 Jan 2001
		NZ 505695 A	01 Mar 2002
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.			

INTERNATIONAL SEARCH REPORT Information on patent family members		International application No. PCT/US2015/029986	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
		NZ 509516 A	31 Jan 2003
		NZ 509517 A	26 Nov 2002
		NZ 509518 A	25 Jul 2003
		PE 128999 A1	16 Dec 1999
		PL 341975 A1	07 May 2001
		TW 487710 B	21 May 2002
		US 6200975 B1	13 Mar 2001
		US 6287780 B1	11 Sep 2001
		US 6310203 B1	30 Oct 2001
		US 6448249 B1	10 Sep 2002
		US 6582916 B1	24 Jun 2003
		US 6699668 B1	02 Mar 2004
		US 7094531 B1	22 Aug 2006
		US 2005042625 A1	24 Feb 2005
		WO 0002893 A1	20 Jan 2000
		WO 0002894 A1	20 Jan 2000
		WO 0002895 A1	20 Jan 2000
		WO 9831830 A1	23 Jul 1998
		WO 9831831 A1	23 Jul 1998
		WO 9850385 A1	12 Nov 1998
		WO 9932501 A1	01 Jul 1999
		WO 9943677 A1	02 Sep 1999
		YU 46500 A	15 Nov 2002
		ZA 9809317 A	25 Aug 1999
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001. Form PCT/ISA/210 (Family Annex)(July 2009)			

INTERNATIONAL SEARCH REPORT		International application No.	
Information on patent family members		PCT/US2015/029986	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
WO 1999/002727 A1	21 January 1999	AU 734636 B2	21 Jun 2001
		AU 8234798 A	08 Feb 1999
		AU 8234898 A	08 Feb 1999
		AU 8234998 A	08 Feb 1999
		AU 8235198 A	08 Feb 1999
		CA 2295955 A1	21 Jan 1999
		EP 0994967 A1	26 Apr 2000
		EP 0994968 A1	26 Apr 2000
		EP 0994969 A1	26 Apr 2000
		EP 0994969 B1	05 Apr 2006
		EP 1002128 A1	24 May 2000
		JP 2001509393 A	24 Jul 2001
		NZ 502088 A	31 May 2002
		US 6297017 B1	02 Oct 2001
		US 6312904 B1	06 Nov 2001
		US 6670120 B1	30 Dec 2003
		US 7056659 B1	06 Jun 2006
		WO 9902725 A1	21 Jan 1999
		WO 9902726 A1	21 Jan 1999
		WO 9902728 A1	21 Jan 1999
WO 2012/162267 A2	29 November 2012	CA 2878787 A1	06 Sep 2013
		CN 103890245 A	25 Jun 2014
		CN 104350374 A	11 Feb 2015
		EP 2710172 A2	26 Mar 2014
		EP 2820394 A1	07 Jan 2015
		HK 1198661 A1	22 May 2015
		JP 2015515263 A	28 May 2015
		SG 194745 A1	30 Dec 2013
		US 2013005585 A1	03 Jan 2013
		US 2013295602 A1	07 Nov 2013
		US 2013296196 A1	07 Nov 2013
		US 2013302807 A1	14 Nov 2013
		US 2013302883 A1	14 Nov 2013
		US 2013302884 A1	14 Nov 2013
		WO 2013130714 A1	06 Sep 2013
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.			

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

INTERNATIONAL SEARCH REPORT Information on patent family members		International application No. PCT/US2015/029986	
This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.			
Patent Document/s Cited in Search Report		Patent Family Member/s	
Publication Number	Publication Date	Publication Number	Publication Date
End of Annex			
<div>Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.</div>			